IN SILICO PREDICTION OF ENHANCED NUTRIENT CONTENT IN PLANTS BY METABOLIC MODELLING

Information

  • Patent Application
  • 20150317458
  • Publication Number
    20150317458
  • Date Filed
    December 05, 2013
    10 years ago
  • Date Published
    November 05, 2015
    8 years ago
Abstract
The present invention relates to a method for identifying at least one metabolic conversion step, the modulation of which increases the amount of a metabolite of interest in a plant cell, plant or plant part, said method comprising establishing a stoichiometric network model for the metabolism of the plant cell, plant or plant part including the synthesis pathway for the metabolite of interest, identifying at least one candidate metabolic conversion step by applying at least one algorithm of Growth-coupled Design, and validating the at least one candidate metabolic conversion step by a constraint-based modeling approach in the stoichiometric network model, wherein an increase in the metabolite of interest occurring in said constraint-based modeling approach is indicative for a metabolic conversion step, the modulation of which increases the amount of the metabolite of interest in the plant cell, plant or plant part. The present invention further relates to a method for generating a plant cell, plant or plant part which produces an increased amount of a metabolite of interest when compared to a control, said method comprising identifying a metabolic conversion step, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, by the method for identifying a metabolic conversion step and modulating the said metabolic conversion step such that the amount of the metabolite of interest is increased in vivo in a plant cell, plant or plant part.
Description

The present invention relates to a method for identifying at least one metabolic conversion step, the modulation of which increases the amount of a metabolite of interest in a plant cell, plant or plant part, said method comprising: establishing a stoichiometric network model for the metabolism of the plant cell, plant or plant part including the synthesis pathway for the metabolite of interest, identifying at least one candidate metabolic conversion step by applying at least one algorithm of Growth-coupled Design, and validating the at least one candidate metabolic conversion step by a constraint-based modeling approach in the stoichiometric network model, wherein an increase in the metabolite of interest occurring in said constraint-based modeling approach is indicative for a metabolic conversion step, the modulation of which increases the amount of the metabolite of interest in the plant cell, plant or plant part. The present invention further relates to a method for generating a plant cell, plant or plant part which produces an increased amount of a metabolite of interest when compared to a control, said method comprising: identifying a metabolic conversion step, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, by the method for identifying a metabolic conversion step and modulating the said metabolic conversion step such that the amount of the metabolite of interest is increased in vivo in a plant cell, plant or plant part.


Higher plants are the major source of food and feed, cereal seeds being the basis of nutrition for a large percentage of the human population. However, the composition of cereal seeds, e.g., rice seeds, is not optimal for human and livestock nutrition, since they often comprise suboptimal amounts of compounds essential for animals and man like, e.g, vitamins, amino acids, or unsaturated fatty acids. Means and methods of obtaining cereal plants producing seeds with an optimized content in certain metabolic compounds are thus needed.


The metabolism of an organism of interest can in principle be modelled in silico by establishing a metabolic network model for said organism, e.g. a stoichiometric network model (e.g. Grafahrend-Belau E., Schreiber, F., Koschützki D., Junker B. H. (2009) Plant Physiology. 149(1), 585-598). This, however, requires profound knowledge on the metabolism of said organism. On the basis of such a model, the flow of metabolites through the network can be calculated in a constraint-based modelling approach like flux-balance analysis for steady state analysis (e.g. Orth J. D., Thiele I., Palsson B. O. (2010) Nature Biotechnology. 28(3), 245-248) or like MOMA (Minimization Of Metabolic Adjustment; Segre D., Vitkup D., Church G. M. (2002) PNAS. 99(23), 15112-15117) or ROOM (Regulatory On/Off Minimization; Shlomi T., Berkman O., Ruppin E. (2005) PNAS. 102(21), 7695-7700) for simulating the distortions within the network caused by the loss of a metabolic conversion step, e.g., by a knockout.


There are different public resources available for collection of biochemical data for plant metabolism needed for the reconstruction of different types of metabolic models. The biochemistry of plant metabolism, especially the primary metabolism, has been studied for many years and can be reviewed in principle in many biochemistry text books. In addition, there are several publicly available databases and online resources existing that contain biochemical data about metabolic reactions and it's occurrence and localization in plants (see Table 1).









TABLE 1







Different data sources for biochemical information


about plant metabolism. The resources are characterized


by reaction properties needed for the reconstruction


of plant-specific metabolic models.











Data source
KEGG
BRENDA
MetaCrop
PlantCyc





Stoichiometry






Directionality





Localization





Ontology






Kinetics





References












The following databases contain almost all necessary biochemical information for plant-specific metabolic models: MetaCrop (Grafahrend-Belau et al., Metacrop: a detailed database for crop plant metabolism. Nucleic Acids Research, 36 (S1):D954-D958, 2008), PlantCyc (Plant Metabolic Network (PNM), 2012, Internet only) and KEGG (Kanehisa and Goto, Kegg: Kyoto encyclopedia of genes and genomes. Nucleic Acids Research, 28(1):27-30, 2000.). All of them support the graphical entrance via organism or pathway specific metabolic network maps whereas the first two contain only plant specific data. KEGG and PlantCyc are highly recommend for getting a system-wide introduction into metabolism: what pathways are present in plants and which reactions are involved. In comparison, MetaCrop is a hand-curated database which contains additional information about reaction directionality and reaction's compartmental localization and their respective references. But MetaCrop does not contain all known metabolic pathways occurring in plants and therefore also BRENDA (Scheer et al., Brenda, the enzyme information system in 2011. Nucleic Acids Research, 39 (suppl 1):D670-D676, 2010.) is very useful by providing organism-specific references for all enzymatic reactions in almost all plant species, if available.


Based on the available biochemical information for the plant of interest the metabolic model can be reconstructed in order to analyse the network structure, calculate feasible flux distributions or explore dynamic properties of the metabolic system.


Based on the models detailed above, algorithms have been devised to solve the bilevel optimization problem of optimizing the production of a metabolite of interest while maintaining a suitable growth rate for the relatively simple metabolic networks of bacteria. These algorithms are able to propose knockout strategies for implementing said optimization (see e.g. Burgard A. P., Pharkya P., Maranas C. D. (2003) Biotechnology and Bioengineering. 84(6):647-657; Tepper N., Shlomi T. (2010) Bioinformatics. 26(4):536-543). However, for the complex metabolism of plants, prediction of knockouts suitable for changing the concentration of a metabolite of interest is a challenge still today. Thus, there is a need for the reliable prediction of metabolic effects. The technical problem underlying the present invention could, thus, be seen as the provision of means and methods for making predictions of relevant metabolic effects and for, thereby, allowing to identify metabolic conversion steps in a metabolism for the production of a metabolite of interest. The technical problem is solved by the embodiments characterized in the claims and herein below.


Accordingly, the present invention relates to a method for identifying at least one metabolic conversion step, the modulation of which increases the amount of a metabolite of interest in a plant cell, plant or plant part, said method comprising: (a) establishing a stoichiometric network model for the metabolism of the plant cell, plant or plant part including the synthesis pathway for the metabolite of interest; (b) identifying at least one candidate metabolic enzymatic conversion step by applying at least one algorithm of Growth-coupled Design; and (c) validating the at least one candidate metabolic conversion step by a constraint-based modeling approach in the stoichiometric network model, wherein an increase in the metabolite of interest occurring in said constraint-based modeling approach is indicative for a metabolic conversion step, the modulation of which increases the amount of the metabolite of interest in the plant cell, plant or plant part.


The method for identifying at least one metabolic conversion step of the present invention, preferably, is an in-silico method. Thus, preferably, most or all of the steps of said method are performed in a computer-assisted mode. Moreover, said method may comprise further steps in addition to the ones explicitly mentioned. Specifically, step a) may, preferably, comprise the further step of generating and/or collecting data required to establish a stoichiometric network model for the metabolism in question or step c) may, preferably, contain the further steps of validating the metabolic conversion step by constructing and analyzing a plant comprising a mutation of the gene encoding the enzyme catalyzing said metabolic conversion step as described herein below.


The term “metabolic conversion step”, as used herein, relates to any chemical or physical modification of a compound comprised by a plant, plant part, plant organ, or plant cell. Preferably, the metabolic conversion step is a chemical conversion of a compound into a chemically different compound. More preferably, the metabolic conversion step is an enzymatically catalyzed chemical reaction. Most preferably, the metabolic conversion step is a chemical reaction catalyzed by a polypeptide having enzymatic properties expressed by the plant cell, i.e. an enzymatic conversion. It is to be understood that the term may refer to any conversion in the metabolism of a plant, including e.g., anabolism, catabolism, and secondary metabolism. It is also to be understood that the term may also refer to the translocation or transport of a compound within the plant of the present invention. Preferably, included by the term metabolic conversion step are, thus, the transport of a compound in the xylem or phloem of a plant, or the transport from one cell compartment into another, preferably, over one or more cellular membranes.


As used herein, the term “plant” relates to a whole plant, a plant part, a plant organ, a plant tissue, or a plant cell. Thus the term includes, preferably, seeds, shoots, stems, leaves, roots (including tubers), and flowers. Plants that are particularly useful in the methods of the invention include all plants which belong to the superfamily Viridiplantae, preferably Tracheophyta, more preferably Spermatophytina, most preferably monocotyledonous and dicotyledonous plants including fodder or forage legumes, ornamental plants, food crops, trees or shrubs selected from the list comprising Acer spp., Actinidia spp., Abelmoschus spp., Agave sisalana, Agropyron spp., Agrostis stolonifera, Allium spp., Amaranthus spp., Ammophila arenaria, Ananas comosus, Annona spp., Apium graveolens, Arachis spp, Artocarpus spp., Asparagus officinalis, Avena spp. (e.g. Avena sativa, Avena fatua, Avena byzantina, Avena fatua var. sativa, Avena hybrida), Averrhoa carambola, Bambusa sp., Benincasa hispida, Bertholletia excelsea, Beta vulgaris, Brassica spp. (e.g. Brassica napus, Brassica rapa ssp. [canola, oilseed rape, turnip rape]), Cadaba farinosa, Camellia sinensis, Canna indica, Cannabis sativa, Capsicum spp., Carex elata, Carica papaya, Carissa macrocarpa, Carya spp., Carthamus tinctorius, Castanea spp., Ceiba pentandra, Cichorium endivia, Cinnamomum spp., Citrullus lanatus, Citrus spp., Cocos spp., Coffea spp., Colocasia esculenta, Cola spp., Corchorus sp., Coriandrum sativum, Corylus spp., Crataegus spp., Crocus sativus, Cucurbita spp., Cucumis spp., Cynara spp., Daucus carota, Desmodium spp., Dimocarpus longan, Dioscorea spp., Diospyros spp., Echinochloa spp., Elaeis (e.g. Elaeis guineensis, Elaeis oleifera), Eleusine coracana, Eragrostis tef, Erianthus sp., Eriobotrya japonica, Eucalyptus sp., Eugenia uniflora, Fagopyrum spp., Fagus spp., Festuca arundinacea, Ficus carica, Fortunella spp., Fragaria spp., Ginkgo biloba, Glycine spp. (e.g. Glycine max, Soja hispida or Soja max), Gossypium hirsutum, Helianthus spp. (e.g. Helianthus annuus), Hemerocallis fulva, Hibiscus spp., Hordeum spp. (e.g. Hordeum vulgare), Ipomoea batatas, Juglans spp., Lactuca sativa, Lathyrus spp., Lens culinaris, Linum usitatissimum, Litchi chinensis, Lotus spp., Luffa acutangula, Lupinus spp., Luzula sylvatica, Lycopersicon spp. (e.g. Lycopersicon esculentum, Lycopersicon lycopersicum, Lycopersicon pyriforme), Macrotyloma spp., Malus spp., Malpighia emarginata, Mammea americana, Mangifera indica, Manihot spp., Manilkara zapota, Medicago sativa, Melilotus spp., Mentha spp., Miscanthus sinensis, Momordica spp., Morus nigra, Musa spp., Nicotiana spp., Olea spp., Opuntia spp., Ornithopus spp., Oryza spp. (e.g. Oryza sativa, Oryza latifolia), Panicum miliaceum, Panicum virgatum, Passiflora edulis, Pastinaca sativa, Pennisetum sp., Persea spp., Petroselinum crispum, Phalaris arundinacea, Phaseolus spp., Phleum pratense, Phoenix spp., Phragmites australis, Physalis spp., Pinus spp., Pistacia vera, Pisum spp., Poa spp., Populus spp., Prosopis spp., Prunus spp., Psidium spp., Punica granatum, Pyrus communis, Quercus spp., Raphanus sativus, Rheum rhabarbarum, Ribes spp., Ricinus communis, Rubus spp., Saccharum spp., Salix sp., Sambucus spp., Secale cereale, Sesamum spp., Sinapis sp., Solanum spp. (e.g. Solanum tuberosum, Solanum integrifolium or Solanum lycopersicum), Sorghum bicolor, Spinacia spp., Syzygium spp., Tagetes spp., Tamarindus indica, Theobroma cacao, Trifolium spp., Tripsacum dactyloides, Triticosecale rimpaui, Triticum spp. (e.g. Triticum aestivum, Triticum durum, Triticum turgidum, Triticum hybernum, Triticum macha, Triticum sativum, Triticum monococcum or Triticum vulgare), Tropaeolum minus, Tropaeolum majus, Vaccinium spp., Vicia spp., Vigna spp., Viola odorata, Vitis spp., Zea mays, Zizania palustris, Ziziphus spp., amongst others.


The term “modulation”, as used herein, relates to a change of a stoichiometric or kinetic parameter of a metabolic conversion step from the corresponding parameter found under physiological conditions in a plant cell, plant, or plant part. Physiological conditions are those which can be observed without modulation of the step. Preferably, the said change is a statistically significant change. The change may be an increase or a decrease. The modulation of a metabolic conversion step and thus, the deviation of a stoichiometric parameter can, e.g., be achieved by deleting or mutating a gene encoding a subunit of an enzyme complex catalyzing a partial reaction of an enzymatic step, such that the amount or identity of the final product is altered. A deviation of a kinetic parameter can, e.g., be achieved by deleting the gene coding for an enzyme catalyzing the metabolic conversion step in question, such that the reaction velocity is reduced to the reaction velocity of the uncatalyzed conversion, which is, preferably, zero. Preferably, modulation encompasses decreasing or increasing the activity of an enzyme catalyzing said metabolic conversion. More preferably, modulation is abolishing the activity of an enzyme catalyzing said metabolic conversion step. Preferably, modulation is achieved by modulation of gene expression. Thus, preferably, the term “modulation” means in relation to expression or gene expression, a process or state in which the level of gene expression is changed by said process or state in comparison to the control plant, wherein the expression level may be increased or decreased. The original, unmodulated expression may be of any kind of expression of a structural RNA (rRNA, tRNA) or mRNA with subsequent translation. The term “modulating the activity” in relation to expression or gene expression shall mean any change of the expression of the gene, leading to an altered concentration of the corresponding polynucleotides or encoded proteins in the cell.


Modulation of an enzymatic activity can be achieved by a variety of methods well known in the art.


Preferably, the modulation is an activation, i.e., preferably, a modulation increasing the activity of an enzyme catalyzing said metabolic conversion. Activation can, preferably, be achieved by application of an activator for the enzyme. More preferably, activation is mediated by introducing into the plant cell one or more molecules of an enzyme catalyzing said metabolic conversion step. Said enzyme may, preferably, be autologous or, more preferably, heterologous. Said enzyme, may be a wildtype enzyme or a mutated enzyme with an increased activity. Also, the enzyme may be introduced into the plant cell as a polypeptide or, more preferably, as an expressible gene.


The term “expression” or “gene expression” relates to transcription of a specific gene or specific genes or a specific genetic construct. The term “expression” or “gene expression” in particular means the transcription of a gene or genes or genetic construct into structural RNA (rRNA, tRNA) or mRNA with or without subsequent translation of the latter into a protein. The process includes transcription of DNA and processing of the resulting mRNA product. The term “increased expression” or “overexpression” as used herein means any form of expression that is additional to the original wild-type expression level. Methods for increasing expression of genes or gene products are well documented in the art and include, for example, overexpression driven by appropriate promoters, the use of transcription enhancers or translation enhancers. Isolated nucleic acids which serve as promoter or enhancer elements may be introduced in an appropriate position (typically upstream) of a non-heterologous form of a polynucleotide so as to upregulate expression of a nucleic acid encoding the polypeptide of interest. For example, endogenous promoters may be altered in vivo by mutation, deletion, and/or substitution (see, Kmiec, U.S. Pat. No. 5,565,350; Zarling et al., WO9322443), or isolated promoters may be introduced into a plant cell in the proper orientation and distance from a gene of the present invention so as to control the expression of the gene. If polypeptide expression is desired, it is generally desirable to include a polyadenylation region at the 3′-end of a polynucleotide coding region. The polyadenylation region can, preferably, be derived from the natural gene, from a variety of other plant genes, or from T-DNA, and the like. The 3′ end sequence to be added may be derived from, for example, the nopaline synthase or octopine synthase genes, or alternatively from another plant gene, or, less preferably, from any other eukaryotic gene. An intron sequence may also be added to the 5′ untranslated region (UTR) or the coding sequence of the partial coding sequence to increase the amount of the mature message that accumulates in the cytosol. Inclusion of a spliceable intron in the transcription unit in both plant and animal expression constructs has been shown to increase gene expression at both the mRNA and protein levels up to 1000-fold (Buchman and Berg (1988) Mol. Cell biol. 8: 4395-4405; Callis et al. (1987) Genes Dev 1:1183-1200). Such intron enhancement of gene expression is typically greatest when placed near the 5′ end of the transcription unit. Use of the maize introns Adh1-S intron 1, 2, and 6, the Bronze-1 intron are known in the art. For general information see: The Maize Handbook, Chapter 116, Freeling and Walbot, Eds., Springer, N.Y. (1994).


Also preferably, the modulation is an inactivation or inhibition, i.e., preferably, a modulation decreasing the activity of an enzyme catalyzing said metabolic conversion. Preferably, the inhibition is reversible, more preferably the inhibition is irreversible, i.e. an inactivation. A direct inhibition is achieved by a compound which binds to the enzyme and thereby inhibits its catalytic activity. Compounds which directly inhibit enzymes in this sense are, preferably, compounds which block the interaction of the enzyme with other proteins or with its substrates. Alternatively, but nevertheless preferred, a direct inhibitor of an enzyme may induce an allosteric change in the conformation of the polypeptide constituting the enzyme. The allosteric change may subsequently block the interaction of the enzyme with other proteins or with its substrates and, thus, interfere with the catalytic activity of the enzyme. Compounds which are suitable as direct inhibitors of enzymes encompass small molecule antagonists (e.g., substrate analogues, allosteric inhibitors), antibodies, aptamers, mutants or variants of the enzyme, a dominant-negative subunit of an enzyme complex, and the like.


Reference herein to an “endogenous” gene not only refers to the gene in question as found in a plant in its natural form (i.e., without there being any human intervention), but also refers to that same gene (or a substantially homologous nucleic acid/gene) in an isolated form subsequently (re)introduced into a plant (a transgene). For example, a transgenic plant containing such a transgene may encounter a substantial reduction of the transgene expression and/or substantial reduction of expression of the endogenous gene. The isolated gene may be isolated from an organism or may be manmade, for example by chemical synthesis.


The term “small molecule antagonist” as used herein refers to a chemical compound that specifically interacts and inhibits the enzyme. A small molecule as used herein preferably has a molecular weight of less than 1000 Da, more preferably, less than 800 Da, less than 500 Da, less than 300 Da, or less than 200 Da. Such small molecules are, preferably, capable of diffusing across cell membranes so that they can enter and reach intracellular sites of action. Suitable chemical compounds encompass small organic molecules. Preferably, the small molecule antagonist is a substrate analogon or an allosteric inhibitor.


The term “antibody” as used herein encompasses all types of an antibody which, preferably, specifically binds to an enzyme and inhibits its activity. Preferably, the antibody of the present invention is a monoclonal antibody, a polyclonal antibody, a single chain antibody, a chimeric antibody or any fragment or derivative of such antibodies being still capable of binding to the enzyme and inhibiting its catalytic activity. Such fragments and derivatives comprised by the term antibody as used herein encompass a bispecific antibody, a synthetic antibody, an Fab, F(ab)2 Fv or scFv fragment, or a chemically modified derivative of any of these antibodies. Specific binding as used in the context of the antibody of the present invention means that the antibody does not cross-react with other polypeptides or, preferably, does not inhibit the activity of other polypeptides. Specific binding and/or inhibition can be tested by various well known techniques. Inhibition is preferably tested by an enzymatic assay determining the activity of the enzyme in question in the presence and in the absence of the antibody. Antibodies or fragments thereof, in general, can be obtained by using methods which are described well known to the skilled person. Monoclonal antibodies can be prepared the techniques which comprise the fusion of mouse myeloma cells to spleen cells derived from immunized mammals and, preferably, immunized mice. Monoclonal antibodies which specifically bind to the enzyme can be prepared using the well known hybridoma technique, the human B cell hybridoma technique, and the EBV hybridoma technique. Specifically binding antibodies which affect at least one catalytic activity can be identified by assays known in the art.


The term “aptamer” as used herein relates to oligonucleic acid or peptide molecules that bind to a specific target polypeptide. Oligonucleic acid aptamers are engineered through repeated rounds of selection or the so called systematic evolution of ligands by exponential enrichment (SELEX technology). Peptide aptamers are designed to interfere with protein interactions inside cells. They usually comprise of a variable peptide loop attached at both ends to a protein scaffold. This double structural constraint shall increase the binding affinity of the peptide aptamer into the nanomolar range. Said variable peptide loop length is, preferably, composed of ten to twenty amino acids, and the scaffold may be any protein having improved solubility and compacity properties, such as thioredoxin-A. Peptide aptamer selection can be made using different systems including, e.g., the yeast two-hybrid system. Aptamers which affect at least one biological activity of an enzyme can be identified by functional assays known in the art.


The term “dominant-negative subunit of an enzyme complex”, as used herein, refers to a subunit of an enzyme complex mutated such that it is still able to bind to the enzyme complex, but not catalytically active. Thus, the non-catalytic dominant-negative subunit disclocates a functional subunit from the complex, leading to a decreased, altered, or abolished activity of the complex.


Inhibition of an enzyme according to the present invention is, preferably, achieved by indirect inhibition wherein the number of molecules of said enzyme present in a plant cell is reduced. Preferably, the number of molecules of said enzyme is reduced to zero, i.e. production of enzyme molecules is abolished. Such a reduction of the number of enzyme molecules is, preferably, accomplished by a reduction or prevention of the expression of the gene coding for said enzyme, i.e. by a reduction or prevention of transcription, a destabilization or increased degradation of the transcripts or a reduction or prevention of the translation of the transcripts into enzyme polypeptides. Compounds which are known to interfere with transcription and/or translation of genes as well as stability of transcripts are inhibitory nucleic acids. Such inhibitory nucleic acids, usually, recognize their target transcripts by hybridization of nucleic acid sequences present in both, the target transcript and the inhibitory nucleic acid, being complementary to each other. Accordingly, for a given transcript with a known nucleic acid sequence, such inhibitors can be designed and synthesized without further ado by the skilled artisan. Suitable assays for testing the activity are known in the art. Specifically, the presence or absence of the target transcript can be measured or the presence or absence of the protein encoded thereby, or its activity, can be measured in the presence and absence of the putative inhibitory nucleic acid. A nucleic acid which, indeed, is an inhibitory nucleic acid can be subsequently identified if in the presence of the inhibitory nucleic acid, the target transcript, the polypeptide, or the enzymatic activity encoded thereby can no longer be detected or is detectable at reduced amounts.


Reference herein to “reducing the number of enzyme molecules” or “reduction or substantial elimination” is taken to mean a decrease in endogenous gene expression and polypeptide levels and/or polypeptide activity relative to control plants. The reduction or substantial elimination is, preferably to a statistically significant extent and, more preferably, in increasing order of preference a reduction of at least 10%, 20%, 30%, 40% or 50%, 60%, 70%, 80%, 85%, 90%, or 95%, 96%, 97%, 98%, 99% or more compared to that of control plants.


Reference herein to “decreased expression” or “reduction or substantial elimination” of expression is taken to mean a decrease in endogenous gene expression and/or polypeptide levels and/or polypeptide activity relative to control plants. The reduction or substantial elimination is in increasing order of preference at least 10%, 20%, 30%, 40% or 50%, 60%, 70%, 80%, 85%, 90%, or 95%, 96%, 97%, 98%, 99% or more reduced compared to that of control plants.


For the reduction or substantial elimination of expression an endogenous gene in a plant, a sufficient length of substantially contiguous nucleotides of a nucleic acid sequence is required. In order to perform gene silencing, this may be as little as 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10 or fewer nucleotides, alternatively this may be as much as the entire gene (including the 5′ and/or 3′ UTR, either in part or in whole). The stretch of substantially contiguous nucleotides may be derived from the nucleic acid encoding the protein of interest (target gene), or from any nucleic acid capable of encoding an orthologue, paralogue or homologue of the protein of interest. Preferably, the stretch of substantially contiguous nucleotides is capable of forming hydrogen bonds with the target gene (either sense or antisense strand), more preferably, the stretch of substantially contiguous nucleotides has, in increasing order of preference, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 100% sequence identity to the target gene (either sense or antisense strand). A nucleic acid sequence encoding a (functional) polypeptide is not a requirement for the various methods discussed herein for the reduction or substantial elimination of expression of an endogenous gene.


This reduction or substantial elimination of expression may be achieved using routine tools and techniques. A preferred method for the reduction or substantial elimination of endogenous gene expression is by introducing and expressing in a plant a genetic construct into which the nucleic acid (in this case a stretch of substantially contiguous nucleotides derived from the gene of interest, or from any nucleic acid capable of encoding an orthologue, paralogue or homologue of any one of the protein of interest) is cloned as an inverted repeat (in part or completely), separated by a spacer (non-coding DNA).


Accordingly, the inhibitor of the invention is, preferably, an inhibitory nucleic acid. More preferably, said inhibitory nucleic acid is selected from the group consisting of: an antisense RNA, a ribozyme, a siRNA, a micro RNA, a morpholino or a triple helix forming agent.


The term “antisense RNA” as used herein refers to an RNA which comprises a nucleic acid sequence which is essentially or perfectly complementary to the target transcript. Preferably, an antisense nucleic acid molecule essentially consists of a nucleic acid sequence being complementary to at least 100 contiguous nucleotides, more preferably, at least 200, at least 300, at least 400 or at least 500 contiguous nucleotides of the target transcript. How to generate and use antisense nucleic acid molecules is well known in the art (see, e.g., Weiss, B. (ed.): Antisense Oligodeoxynucleotides and Antisense RNA: Novel Pharmacological and Therapeutic Agents, CRC Press, Boca Raton, Fla., 1997.). The antisense nucleic acid sequence can be produced biologically using an expression vector into which a nucleic acid sequence has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest). Preferably, production of antisense nucleic acid sequences in plants occurs by means of a stably integrated nucleic acid construct comprising a promoter, an operably linked antisense oligonucleotide, and a terminator.


The nucleic acid molecules used for silencing in the methods of the invention (whether introduced into a plant or generated in situ) hybridize with or bind to mRNA transcripts and/or genomic DNA encoding a polypeptide to thereby inhibit expression of the protein, e.g., by inhibiting transcription and/or translation. The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid sequence which binds to DNA duplexes, through specific interactions in the major groove of the double helix. Antisense nucleic acid sequences may be introduced into a plant by transformation or direct injection at a specific tissue site. Alternatively, antisense nucleic acid sequences can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense nucleic acid sequences can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface, e.g., by linking the antisense nucleic acid sequence to peptides or antibodies which bind to cell surface receptors or antigens. The antisense nucleic acid sequences can also be delivered to cells using the vectors described herein.


According to a further aspect, the antisense nucleic acid sequence is an a-anomeric nucleic acid sequence. An a-anomeric nucleic acid sequence forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gaultier et al. (1987) Nucl Ac Res 15: 6625-6641). The antisense nucleic acid sequence may also comprise a 2′-o-methylribonucleotide (Inoue et al. (1987) Nucl Ac Res 15, 6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBS Lett. 215, 327-330).


The term “ribozyme” as used herein refers to catalytic RNA molecules possessing a well defined tertiary structure that allows for catalyzing either the hydrolysis of one of their own phosphodiester bonds (self-cleaving ribozymes), or the hydrolysis of bonds in other RNAs, but they have also been found to catalyze the aminotransferase activity of the ribosome. The ribozymes envisaged in accordance with the present invention are, preferably, those which specifically hydrolyse the target transcripts. In particular, hammerhead ribozymes are preferred in accordance with the present invention. How to generate and use such ribozymes is well known in the art (see, e.g., Hean J, Weinberg M S (2008). “The Hammerhead Ribozyme Revisited: New Biological Insights for the Development of Therapeutic Agents and for Reverse Genomics Applications”. In Morris K L. RNA and the Regulation of Gene Expression: A Hidden Layer of Complexity. Norfolk, England: Caister Academic Press).


The term “siRNA” as used herein refers to small interfering RNAs (siRNAs) which are complementary to target RNAs (encoding a gene of interest) and diminish or abolish gene expression by RNA interference (RNAi). Without being bound by theory, RNAi is generally used to silence expression of a gene of interest by targeting mRNA. Briefly, the process of RNAi in the cell is initiated by double stranded RNAs (dsRNAs) which are cleaved by a ribonuclease, thus producing siRNA duplexes. The siRNA binds to another intracellular enzyme complex which is thereby activated to target whatever mRNA molecules are homologous (or complementary) to the siRNA sequence. The function of the complex is to target the homologous mRNA molecule through base pairing interactions between one of the siRNA strands and the target mRNA. The mRNA is then cleaved approximately 12 nucleotides from the 3′ terminus of the siRNA and degraded. In this manner, specific mRNAs can be targeted and degraded, thereby resulting in a loss of protein expression from the targeted mRNA. A complementary nucleotide sequence as used herein refers to the region on the RNA strand that is complementary to an RNA transcript of a portion of the target gene. The term “dsRNA” refers to RNA having a duplex structure comprising two complementary and anti-parallel nucleic acid strands. Not all nucleotides of a dsRNA necessarily exhibit complete Watson-Crick base pairs; the two RNA strands may be substantially complementary. The RNA strands forming the dsRNA may have the same or a different number of nucleotides, with the maximum number of base pairs being the number of nucleotides in the shortest strand of the dsRNA. Preferably, the dsRNA is no more than 49, more preferably less than 25, and most preferably between 19 and 23, nucleotides in length. dsRNAs of this length are particularly efficient in inhibiting the expression of the target gene using RNAi techniques. dsRNAs are subsequently degraded by a ribonuclease enzyme into short interfering RNAs (siRNAs). The complementary regions of the siRNA allow sufficient hybridization of the siRNA to the target RNA and thus mediate RNAi. In mammalian cells, siRNAs are approximately 21-25 nucleotides in length. The siRNA sequence needs to be of sufficient length to bring the siRNA and target RNA together through complementary base-pairing interactions. The siRNA used with the Tet expression system of the invention may be of varying lengths. The length of the siRNA is preferably greater than or equal to ten nucleotides and of sufficient length to stably interact with the target RNA; specifically 10-30 nucleotides; more specifically any integer between 10 and 30 nucleotides, most preferably 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30. By “sufficient length” is meant an oligonucleotide of greater than or equal to 15 nucleotides that is of a length great enough to provide the intended function under the expected condition. By “stably interact” is meant interaction of the small interfering RNA with target nucleic acid (e.g., by forming hydrogen bonds with complementary nucleotides in the target under physiological conditions). Generally, such complementarity is 100% between the siRNA and the RNA target, but can be less if desired, preferably 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. For example, 19 bases out of 21 bases may be base-paired. In some instances, where selection between various allelic variants is desired, 100% complementary to the target gene is required in order to effectively discern the target sequence from the other allelic sequence. When selecting between allelic targets, choice of length is also an important factor because it is the other factor involved in the percent complementary and the ability to differentiate between allelic differences. Methods relating to the use of RNAi to silence genes in organisms, including C. elegans, Drosophila, plants, and mammals, are known in the art (see, e.g., WO 0129058; WO 09932619; and Elbashir (2001), Nature 411: 494-498).


The term “microRNA” as used herein refers to a self complementary single-stranded RNA which comprises a sense and an antisense strand linked via a hairpin structure. The micro RNA comprise a strand which is complementary to an RNA targeting sequences comprised by a transcript to be downregulated. micro RNAs are processed into smaller single stranded RNAs and, therefore, presumably also act via the RNAi mechanisms. How to design and to synthesise microRNAs which specifically degrade a transcript of interest is known in the art and described, e.g., in EP 1 504 126 A2 or Dimond (2010), Genetic Engineering & Biotechnology News 30 (6):1.


Another example of an RNA silencing method involves the introduction of nucleic acid sequences or parts thereof (in this case a stretch of substantially contiguous nucleotides derived from the gene of interest, or from any nucleic acid capable of encoding an orthologue, paralogue or homologue of the protein of interest) in a sense orientation into a plant. “Sense orientation” refers to a DNA sequence that is homologous to an mRNA transcript thereof. Introduced into a plant would therefore be at least one copy of the nucleic acid sequence. The additional nucleic acid sequence will reduce expression of the endogenous gene, giving rise to a phenomenon known as co-suppression. The reduction of gene expression will be more pronounced if several additional copies of a nucleic acid sequence are introduced into the plant, as there is a positive correlation between high transcript levels and the triggering of co-suppression.


The term “morpholino” refers to a synthetic nucleic acid molecule having a length of 20 to 30 nucleotides, preferably, about 25 nucleotides. Morpholinos bind to complementary sequences of target transcripts by standard nucleic acid base-pairing. They have standard nucleic acid bases which are bound to morpholine rings instead of deoxyribose rings and linked through phosphorodiamidate groups instead of phosphates. The replacement of anionic phosphates with the uncharged phosphorodiamidate groups eliminates ionization in the usual physiological pH range, so morpholinos in organisms or cells are uncharged molecules. The entire backbone of a morpholino is made from these modified subunits. Unlike inhibitory small RNA molecules, morpholinos do not degrade their target RNA molecules. Rather, they sterically block binding to a target sequence within an RNA and simply getting in the way of molecules that might otherwise interact with the RNA (see, e.g., Summerton (1999), Biochimica et Biophysica Acta 1489 (1): 141-58).


The term “triple helix forming agent” as used herein refers to oligonucleotides which are capable of forming a triple helix with DNA and, in particular, which interfere upon forming of the triple-helix with transcription initiation or elongation of a desired target gene such as RAGE in the case of the inhibitor of the present invention. The design and manufacture of triple helix forming agents is well known in the art (see, e.g., Vasquez (2002), Quart Rev Biophys 35: 89-107).


For optimal performance, the gene silencing techniques used for reducing expression in a plant of an endogenous gene require the use of nucleic acid sequences from monocotyledonous plants for transformation of monocotyledonous plants, and from dicotyledonous plants for transformation of dicotyledonous plants. Preferably, a nucleic acid sequence from any given plant species is introduced into that same species. For example, a nucleic acid sequence from rice is transformed into a rice plant. However, it is not an absolute requirement that the nucleic acid sequence to be introduced originates from the same plant species as the plant in which it will be introduced. It is sufficient that there is substantial homology between the endogenous target gene and the nucleic acid to be introduced.


Abolishing production of enzyme molecules, i.e. reduction by 100%, is accomplished in a variety of ways. The gene coding for said enzyme can, e.g., be deleted or mutated in a way such that a functional enzyme can no longer be expressed (Knockout-mutation, KO-mutation). Alternatively, said gene may be replaced, e.g. by a non-functional gene, by a mutant copy coding for an inactive variant, or by a gene coding for a selectable marker, e.g., preferably, by homologous recombination. Homologous recombination allows introduction into a genome of a selected nucleic acid at a defined selected position. Homologous recombination is a standard technology used routinely in biological sciences for lower organisms such as yeast or the moss Physcomitrella. Methods for performing homologous recombination in plants have been described not only for model plants (Offringa et al. (1990) EMBO J 9(10): 3077-84) but also for crop plants, for example rice (Terada et al. (2002) Nat Biotech 20(10): 1030-4; Iida and Terada (2004) Curr Opin Biotech 15(2): 132-8), and approaches exist that are generally applicable regardless of the target organism (Miller et al, Nature Biotechnol. 25, 778-785, 2007). It is known to the skilled person that such deletion, mutation, or replacement will have to be performed for each copy of the wildtype gene coding for said enzyme available in said plant cell. It is also known to the skilled person that said deletion, mutation, or replacement may, but does not have to, extend to isoenzymes, preferably isoenzymes encoded and/or active in other compartments of the cell. A KO-mutation may also be achieved by insertion mutagenesis (for example, T-DNA insertion or transposon insertion) or by strategies as described by, among others, Angell and Baulcombe ((1999) Plant J 20(3): 357-62), (Amplicon VIGS WO 98/36083), or Baulcombe (WO 99/15682).


Preferably, a reduction of enzyme molecules is achieved by TILING. The term “TILLING” is an abbreviation of “Targeted Induced Local Lesions In Genomes” and refers to a mutagenesis technology useful to generate and/or identify nucleic acids encoding proteins with modified expression and/or activity. TILLING also allows selection of plants carrying such mutant variants. These mutant variants may exhibit modified expression, either in strength or in location or in timing (if the mutations affect the promoter for example). These mutant variants may exhibit higher activity than that exhibited by the gene in its natural form. TILLING combines high-density mutagenesis with high-throughput screening methods. The steps typically followed in TILLING are: (a) EMS mutagenesis (Redei G P and Koncz C (1992) In Methods in Arabidopsis Research, Koncz C, Chua N H, Schell J, eds. Singapore, World Scientific Publishing Co, pp. 16-82; Feldmann et al., (1994) In Meyerowitz E M, Somerville C R, eds, Arabidopsis. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp 137-172; Lightner J and Caspar T (1998) In J Martinez-Zapater, J Salinas, eds, Methods on Molecular Biology, Vol. 82. Humana Press, Totowa, N.J., pp 91-104); (b) DNA preparation and pooling of individuals; (c) PCR amplification of a region of interest; (d) denaturation and annealing to allow formation of heteroduplexes; (e) DHPLC, where the presence of a heteroduplex in a pool is detected as an extra peak in the chromatogram; (f) identification of the mutant individual; and (g) sequencing of the mutant PCR product. Methods for TILLING are well known in the art (McCallum et al., (2000) Nat Biotechnol 18: 455-457; reviewed by Stemple (2004) Nat Rev Genet 5(2): 145-50).


Alternatively, a screening program may be set up to identify in a plant population natural variants of a gene, which variants encode polypeptides with reduced activity. Such natural variants may also be used for example, to perform homologous recombination.


Described above are examples of various methods for the reduction or substantial elimination of expression in a plant of an endogenous gene. A person skilled in the art would readily be able to adapt the aforementioned methods for silencing so as to achieve reduction of expression of an endogenous gene in a whole plant or in parts thereof through the use of an appropriate promoter, for example.


The term “significant”, as used in this specification, relates to statistical significance. Whether a data set supports a hypothesis in a statistically significant way can be determined without further ado by the person skilled in the art using various well known statistic evaluation tools, e.g., determination of confidence intervals, p-value determination, Student's t-test, Mann-Whitney test etc. Preferred confidence intervals are at least 90%, at least 95%, at least 97%, at least 98% or at least 99%. The p-values are, preferably, 0.1, 0.05, 0.01, 0.005, or 0.0001.


The term “amount” relates to the quantity of a metabolite or compound of the present invention. Preferably, the amount is determined as the concentration of the metabolite in the cell, as the fraction of biomass or dry mass, or any other method suitable for determining a quantity of a specific substance. An increase in amount is preferably a significant increase, more preferably an increase of the amount is an increase by 2-5%, 5-10%, 10-20%, 20-50%, 50-100%, 10-100%, 100-200%, or 100-500% as compared to a control plant. Most preferably, an increase in amount is an increase by at least 2%, 5%, 10%, 20%, 30%, 40%, 50%, 75%, 100%, 200%, 300%, 400%, or at least 500% as compared to a control plant. The term “biomass” as used herein is intended to refer to the total weight of a plant. Within the definition of biomass, a distinction may be made between the biomass of one or more parts of a plant, which may include any one or more of the following: aboveground parts such as but not limited to shoot biomass, seed biomass, leaf biomass, etc.; aboveground harvestable parts such as but not limited to shoot biomass, seed biomass, leaf biomass, etc.; parts below ground, such as but not limited to root biomass, etc.; harvestable parts below ground, such as but not limited to root biomass, etc.; vegetative biomass such as root biomass, shoot biomass, etc.; reproductive organs; and propagules, such as seed.


As used herein, the term “metabolite of interest” relates to any compound of the primary or secondary metabolism of a plant. Preferably, the metabolite of interest is a compound not synthesized by the body cells of at least one animal species, preferably at least one mammalian species, more preferably at least one livestock species, or, most preferably, man. Preferably, the metabolite of interest is an amino acid, more preferably the metabolite is arginine, cysteine, glycine, glutamine, histidine, proline, serine, tyrosine, phenylalanine, valine, threonine, tryptophan, isoleucine, methionine, leucine, lysine, or histidine, most preferably the L-form of the respective amino acid. Also included as metabolites of interest are, preferably, vitamins, more preferably, Vitamin A (Retinol), Vitamin B1 (Thiamine), Vitamin C (Ascorbic acid), a form of Vitamin D (Calciferol), Vitamin B2 (Riboflavin), Vitamin E (Tocopherol), Vitamin K1 (Phylloquinone), Vitamin B5 (Pantothenic acid), Vitamin B7 (Biotin), B6 (Pyridoxine), Vitamin B3 (Niacin), or Vitamin B9 (Folic acid). Also included as metabolites of interest are, preferably, fatty acid, more preferably, unsaturated fatty acid, most preferably, polyunsaturated fatty acids. Further included as metabolites of interest are, preferably, carbohydrates, more preferably, sugars, starch, and the like.


The term “network model”, as used herein, relates to a representation and simulation of metabolic and physical conversions that determine the physiological and biochemical properties of a plant. Preferably, the network model comprises the metabolic conversions of the synthesis pathway for the metabolite of interest. More preferably, the network model comprises all metabolic conversions having an impact on the amount of the metabolite of interest. The term “having an impact” relates to a metabolic conversion which, when abolished, leads to a deviation from normal of the amount of the metabolite of interest of at least 5%, at least 10%, at least 25%, at least 50%, at least 100%, at least 200%, at least 500%, or at least 1000%. Even more preferably, the network model comprises all metabolic conversions of the complete primary metabolism of the plant, i.e. preferably, the network model comprises all relevant metabolic conversion steps of the anabolic and catabolic pathways of the metabolism of the plant. Most preferably, the network model comprises all known metabolic conversions of a plant. The term “known metabolic conversion”, preferably, includes metabolic conversions known from in silico predictions of enzymes encoded in the genome of said plant.


The term “stoichiometric network model”, as used herein, relates to a network model comprising data related to the stoichiometry of educts and products of the metabolic conversions comprised in said network model. Preferably, the stoichometric network model also comprises data related to the composition of the plant, plant part, plant tissue, or plant cell of interest. It is, thus, understood by the skilled person that a stoichiometric network model, preferably, is specific for a specific plant, plant part, or plant tissue having said composition. More preferably, the stoichiometric network model is a stoichiometric network model of rice, most preferably of rice seeds. In a preferred embodiment, the stoichiometric network model comprises the data of Table 3 below, more preferably, the data of Table 3 and FIG. 1. Abbreviations in Table 3 are explained in Table 4. Preferably, the stoichiometric network model does not comprise kinetic data related to the metabolic conversions. Preferably, the stoichiometric network model is implemented in a data processor, more preferably a computer.


As used herein, the term “algorithm of Growth-coupled Design” relates to an algorithm solving a bilevel optimization, wherein the first optimization is the maximization of the production of the amount of the metabolite of interest, and wherein the second optimization is maintenance of metabolic conversions leading to the production of growth resources. It is understood by the skilled person that the amount of metabolite of interest obtainable, i.e. the first optimization, will depend strongly on the identity of the metabolite of interest. E.g., in case the metabolite is an amino acid, preferably leucine, preferred amounts are at least 0.001 mmol*g dry weight (gDW)−1*h−1, at least 0.002 mmol*gDW−1*h−1, at least 0.003 mmol*gDW−1*h−1, at least 0.004 mmol*gDW−1*h−1, at least 0.005 mmol*gDW−1*h−1, at least 0.01 mmol*gDW−1*h−1, at least 0.02 mmol*gDW−1*h−1, at least 0.05 mmol*gDW−1*h−1, or at least 0.1 mmol*gDW−1*h−1. Preferably, said maintenance of metabolic conversions leading to the production of growth resources, i.e. the second optimization, allows for a growth rate of at least 0.0014/h, at least 0.0019/h, at least 0.0024/h, at least 0.0029/h, at least 0.0034/h, at least 0.0038/h, or at least 0.0043/h. More preferably, said maintenance of metabolic conversions leading to the production of growth resources allows for a growth rate, i.e., preferably, to a biomass production, of at least 0.001 mmol*g dry weight (gDW)−1*h−1, at least 0.002 mmol*gDW−1*h−1, at least 0.003 mmol*gDW−1*h−1, at least 0.004 mmol*gDW−1*h−1, at least 0.005 mmol*gDW−1*h−1, at least 0.01 mmol*gDW−1*h−1, at least 0.02 mmol*gDW−1*h−1, at least 0.05 mmol*gDW−1*h−1, or at least 0.1 mmol*gDW−1*h−1. Preferably, the amount of biomass is calculated based on fixed substrate uptake rates for the metabolic network of the plant cell, plant or plant part and/or the plant-specific nutritional composition in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced or enhanced. Preferably, the bilevel optimization is solved by calculating the amount of the metabolite of interest based on the calculated amount of biomass. More preferably, the bilevel optimization is solved by calculating the product of the amount of metabolite of interest and the growth rate obtainable, i.e., preferably, the yield, for a specific modulation or a specific set of modulations. Preferably, the algorithm of Growth-coupled Design is a mathematical algorithm or a genetic algorithm. More preferably, the algorithm of Growth-coupled Design is capable of at least calculating the amount of the metabolite of interest obtained in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced and the algorithm of Growth-coupled Design is capable of thereby identifying at least one metabolic enzymatic conversion step the reduction of which yields the maximum amount for the metabolite of interest. Most preferably, the mathematical algorithm is OptKnock or RobustKnock (see Table 2 below) and/or the genetic algorithm is OptGene (see Table 2). In a preferred embodiment, OptKnock and/or RobustKnock are to be used if one to four metabolic enzymatic conversion step(s), the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified. In another preferred embodiment, OptGene is to be used if more than four metabolic enzymatic conversion steps, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified. Examples of preferred algorithms, their uses, and relevant publications are shown in table 2. Preferably, the algorithm is implemented in a data processor, more preferably a computer.


As used herein, the term “constraint-based modeling” relates to modeling the metabolism of a plant based on physicochemical constraints and/or reaction stoichiometry constraints arising from the requirement that fluxes consuming and producing metabolites are balanced. Preferably, the term relates to a modeling based on the constraints thermodynamic directionality and/or enzymatic capacity and/or reaction stoichiometry. Preferably, the metabolites considered are low-molecular weight organic compound. More preferably, in addition protons and/or electrons (reducing equivalents) are taken into account in said modeling.


In a preferred embodiment, the present invention relates to the method as described supra, wherein said modulation of a metabolic conversion step encompasses decreasing or increasing the activity of at least one enzyme catalyzing the metabolic conversion step in the plant cell.


In another preferred embodiment, the present invention relates to the method as described supra, wherein said stoichiometric network model for the metabolism of the plant cell, plant or plant part comprises all relevant metabolic conversion steps of the anabolic and catabolic pathways of the metabolism of the plant cell, plant or plant part and wherein each metabolic conversion step is defined by its underlying reaction stoichiometry.


In a further preferred embodiment, the present invention relates to the method as described supra, wherein said at least one algorithm for solving the Growth-coupled Design (i) is capable of at least calculating the amount of the metabolite of interest obtained in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced and (ii) is capable of thereby identifying at least one metabolic enzymatic conversion step the reduction of which yields the maximum amount for the metabolite of interest.


In yet another preferred embodiment, the present invention relates to the method as described supra, wherein the amount of the metabolite of interest is calculated based on the calculated amount of biomass.


In an also preferred embodiment, the present invention relates to the method as described supra, wherein said amount of biomass is calculated based on (i) fixed substrate uptake rates for the metabolic network of the plant cell, plant or plant part and/or (ii) the plant-specific nutritional composition in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced or enhanced.


In another preferred embodiment, the present invention relates to the method as described supra, wherein said at least one algorithm for solving the Growth-coupled Design is selected from the group consisting of: OptKnock, RobustKnock and OptGene.


In a further preferred embodiment, the present invention relates to the method as described supra, wherein OptKnock and/or RobustKnock are to be used if one to four metabolic enzymatic conversion step(s), the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified.


In an also preferred embodiment, the present invention relates to the method as described supra, wherein OptGene is to be used if more than four metabolic enzymatic conversion steps, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified.


In a further preferred embodiment, the present invention relates to the method as described supra, wherein said plant cell, plant or plant part is a rice cell, rice plant, rice plant part, or rice seed.


In yet another preferred embodiment, the present invention relates to the method as described supra, wherein said metabolite of interest is an amino acid, a fatty acid, or a carbohydrate.


In a further preferred embodiment, the present invention relates to the method as described supra, wherein steps (a) to (c) of said method are automated by implementation on a data processing device.


In another preferred embodiment, the present invention relates to the method as described supra, wherein said method further comprises the further step of:


(d) determining whether the metabolic enzymatic conversion step validated in step (c) increases the metabolite of interest in the plant cell, plant or plant part by modulating the said metabolic enzymatic conversion step in a plant cell, plant or plant part in vivo.


The definitions made above apply mutatis mutandis to the following embodiments


The present invention further relates to a method for generating a plant cell, plant or plant part which produces an increased amount of a metabolite of interest when compared to a control, said method comprising: (a) identifying a metabolic conversion step, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, by the method of any one of claims 1 to 13; and (b) stably modulating the said metabolic enzymatic conversion step such that the amount of the metabolite of interest is increased in vivo in a plant cell, plant or plant part.


The method for generating a plant cell, plant or plant part of the present invention, preferably, is an in vitro method. Moreover, it may comprise steps in addition to those explicitly mentioned above. For example, further steps may relate, e.g., to introducing a compound modulating the said metabolic conversion step in step b). Moreover, one or more of said steps may be performed by automated equipment. Preferably, the generation of said plant cell does not rely exclusively on natural phenomena such as crossing and selection.


As used herein, the term “stably modulating” relates to modulating as defined herein above over an extended period of time. Preferably, stably modulating relates to modulating a metabolic conversion for at least one week, at least two weeks, at least three weeks, at least four weeks, at least one month, at least two months, at least three months, at least six months, at least one year, or more than one year. This kind of stable modulation can, e.g. be achieved by applying an inhibitor to the plant, which is not removed from metabolism to a significant extent over the said period of time, or by introducing a regulable gene into said plant providing for the intended modulation of the amount of the metabolite of interest and applying an inducer or repressor of said inducible gene to said plant for said period of time. More preferably, stably modulating relates to modulating a metabolic conversion starting at a selected point in time and continuing at least until the plant, plant tissue, plant part, or plant cell is harvested or until the end of the growing season. This kind of stable modulation can, e.g. be achieved by introducing a regulable gene into said plant providing for the intended modulation of the amount of the metabolite of interest and applying an inducer or a repressor of said inducible gene to said plant. It is understood by the skilled artisan that said application of an inducer may have to be repeated in order to maintain induction of the inducible gene and, thereby, the modulation of the metabolite of interest. This kind of modulation can, e.g., also be obtained by introducing a genetic construct into said plant, which can be induced to undergo a genetic rearrangement, wherein said genetic rearrangement produces a modified genetic construct being constitutively active in modulating said metabolite of interest. Most preferably, stably modulating relates to modulating a metabolic conversion in a manner stably inherited over at least two generations. Such stable modulation can, e.g. be achieved by introducing a gene coding for an enzyme modulating the amount of a metabolite of interest or by deleting or mutating a gene coding for an enzyme modulating the amount of a metabolite of interest as described herein above. It is understood that stable modulation according to the present invention can also be achieved by indirect methods as described herein above.


The present invention further relates to a plant cell, plant or plant part obtainable by the method for generating a plant cell, plant or plant part, which produces an increased amount of a metabolite of interest when compared to a control, of the present invention.


The present invention also relates to a device, preferably a data processing device, comprising a data processor having tangibly embedded least one of the algorithms of the invention.


The term “device” as used herein relates to a system of means comprising at least the aforementioned means operatively linked to each other as to allow the identification of at least one candidate metabolic conversion step of the present invention. How to link the means in an operating manner will depend on the type of means included into the device. Preferably, the device is capable of generating an output file containing at least one candidate metabolic step according to the invention identified based on applying said algorithm on the stoichiometric network of the present invention.


The present invention further relates to a data carrier comprising the data defining the stoichiometric network model of the present invention.


As used herein, the term data carrier relates to a physical object comprising the data of the present invention in a form legible, preferably directly or indirectly, to a human or a data processing device. Preferably, data are stored in analogous form; more preferably, data are stored in digital form. Preferably, data are stored electronically or magnetically on the data carrier. It is understood that, preferably, a data carrier is not of any predetermined form or configuration. Preferably, the data carrier is a radio-frequency identification (RFID) chip, a memory chip, a CD or DVD, a hard disk, or the like. It is understood by the skilled person that data may be stored in an encrypted form on the data carrier.


All references cited in this specification are herewith incorporated by reference with respect to their entire disclosure content and the disclosure content specifically mentioned in this specification.





FIGURE LEGENDS


FIG. 1: Different algorithmic approaches for Growth-coupled Design. Regarding their programmatic approach the above mentioned algorithms can be classified as follows: a) Mathematical approach: Bilevel Optimization problem (i.e. OptKnock and RobustKnock) and b) Evolutionary Approach: Genetic algorithm (i.e. OptGene). Figures are modified from Burgard et al., 2003; Patil et al., 2005.



FIG. 2: Flux maps for selected knock-out mutants. A) Flux distribution map of Lys-2KO-RK. B) Flux distribution map of Lys-3KO-OK. Metabolite abbreviations are explained in Table 4





The following Examples shall merely illustrate the invention. They shall not be construed, whatsoever, to limit the scope of the invention.


EXAMPLE 1
Reconstruction of Rice Seed Model

A metabolic model of rice seeds was reconstructed in accordance with the reconstruction procedure stated in (Grafahrend-Belau et al., 2009). This bottom-up approach of metabolic reconstruction is based on rice-specific seed knowledge about precise biomass composition as well as definition of model system boundaries such as uptake and excretion reactions for nutrients and other metabolites. Accordingly, the rice seed model only contains reactions and pathways of primary metabolism that are required for biochemical route from affiliated biochemical compounds to synthesis of all specific biomass precursors. Each participating reaction is characterized by its reaction stoichiometry, compartmental localization and literature evidence verifying the reactions' occurrence in rice or other taxonomical related plants such as maize, wheat or barley. Due to lack of available plant and especially rice specific data the following assumption for the overall modeling process are taken into account:

    • Each reaction is treated as reversible unless it is explicitly declared as irreversible in literature.
    • Each individual metabolic component (reaction or metabolite) is assigned to one of the following compartments: extracellular media, cytosol, plastid or mitochondrion. In case, there is no localization information available or this metabolic component appears in another compartment than these mentioned above, it is modelled as cytosolic component.
    • Multi-enzyme complexes are modelled by one single reaction whose reaction stoichiometry is defined by net reaction of all subunits of this enzyme.


The final metabolic model was functionally tested and verified under different growth conditions and genetic modifications elsewhere.


EXAMPLE 2
Constraint-Based Modeling

An existing metabolic reconstruction can be used to assess phenotypic properties and functional states of the model organism by applying methods of constraint-based modeling. Assuming metabolic steady state, the system of mass balance equations derived from a metabolic network of n reactions and m metabolites can be represented as follows:






S·v=0





with





αj≦vj≦βj


where S is the stoichiometric matrix (m×n) and v is a flux vector of n metabolic fluxes, with αi as lower and βi as upper bounds for each vi, respectively. The most common constraint-based method is flux balance analysis that uses the principle of linear programming to solve the system of mass balance equations by defining an objective function and searching the allowable solution space for an optimal flux distribution that maximizes or minimizes the objective function (Savinell and Palsson, 1992). While flux balance analysis is preferred for prediction of wild type flux distributions, the following constraint-based methods were used for perturbed networks (including one or more reaction knock-outs): MOMA (Segre et al., 2003) and ROOM (Shlomi et al., 2005).


The whole model simulation including different constraint-based methods and algorithms was achieved using the COBRA toolbox version 2.0.3 (downloaded at Oct. 26, 2011) which is an opensource bundle of M-scripts for model reconstruction and model analysis (Schellenberger et al., 2011). The commercial mathematical environment Matlab R2011b version 7.13 as well as the commercial solver CPLEX from IBM was used for execution of these COBRA scripts. In addition, the SBML toolbox version 4.0.1 and libSBML version 5.1.0b0 are required to import the metabolic model in SBML file format into Matlab for further analysis. The resulting flux distributions of the rice seed model are visualized using the PathwayExplorer add-on FluxViz.


EXAMPLE 3
Growth-Coupled Design

An application of constraint-based modeling is the Growth-coupled Design which is an ‘in-silico’ metabolic engineering strategy coupling metabolite production to growth rate. The following algorithmic approaches of Growth-coupled Design were used to identify knock-out mutants of rice seeds with increased amount of different essential amino acids: the bilevel optimization algorithms OptKnock and RobustKnock, and the genetic algorithm OptGene. Beside the different programmatic approach, all algorithms of Growth-coupled Design provide knock-out mutants characterized by a number of one or more metabolic reactions whose knock-out support production of particular metabolite of interest (FIG. 1).


EXAMPLE 4
Predicting Knock-Out Mutants for Rice Seeds with Enhanced Content of Essential Amino Acids

For the purpose of using the Growth-coupled Design to predict knock-out mutants for rice seeds with enhanced content of essential amino acids, the stoichiometric model as well as the corresponding network map needs to be enlarged by the following:

    • 1. Addition of all reactions needed for synthesis of particular essential amino acids, if they are not yet included in the stoichiometric model
    • 2. Addition of (artificial) exchange reaction for particular essential amino acid


The following simulation settings were used for all simulation runs irrespective of the used algorithm:

    • Uptake rate of sucrose as main carbon source was fixed to 0.014 mmol gDW−1 h−1 (Furbank et al., 2001)
    • Maximum number of knock-outs is varied between 2 and 4 for OptKnock and RobustKnock, whereas this number was limited to 6 for OptGene
    • Minimal biomass threshold was fixed to 50% of optimal value (obtained by flux balance analysis under wild type conditions) for OptKnock and RobustKnock
    • Iterations: OptKnock and RobustKnock were run for each number of allowable knock-outs; OptGene was run for five times


EXAMPLE 5
Analysing Enhanced Production of Essential Amino Acids in Rice Seed Metabolism

For the purpose of analysing enhanced production of essential amino acids in rice seed metabolism the following 3 algorithmic approaches for prediction of multiple knock-out mutants were used:

    • OptKnock,
    • RobustKnock and
    • OptGene.


The following essential amino acids were studied in detail: lysine, methionine, cysteine, threonine and tryptophan. Each listed amino acid was analysed using each of the above mentioned algorithms by application of defined simulation settings (see section ‘Experimental Procedures’ for further details). The utilization of similar simulation settings for these approaches allows a general comparison between them regarding their solution quality, their maximum number of knock-outs and their average duration time for one simulation run (see Table 5).









TABLE 5







Evaluation of different algorithms for Growth-coupled Design.


The results of Growth-coupled Design for the 5 essential amino acids


were compared regarding their solution quality, number of feasible


knock-outs and average duration for one simulation run. The property


‘Total’ is a measure how often the different algorithms


found the (best) solution for each amino acid: best solution: 3 pts.,


second-best solution: 2 pts., worst solution: 1 pt. These points were


cumulated in the end.










Property
OptKnock
RobustKnock
OptGene













Best solution
1
3
2


No solution
2
1
1


Total
8
12
11


Max number of KOs
5
2
6









Duration
Exponential increase
about 30 minutes;



by enhancing the
dependent on number



number of knock-outs
of generations









By comparing the results of these different algorithms there is no clear preference for one of these algorithms. The both bilevel optimization algorithms OptKnock and RobustKnock are suitable to predict 2-4 knock-outs whereas RobustKnock delivers KO mutants with a higher ranking SSP value in total. In contrast, OptGene can be preferentially used to provide multiple KO mutants with more than 4 knock-outs which are not feasible with the other two algorithms due to the increased mathematical complexity.


EXAMPLE 6
Evaluation of KO Mutants

The obtained KO mutants from different simulations of Growth-coupled Design were evaluated by the following ranking criteria (Feist et al., 2010):

    • 1. Product Yield YP: Maximum amount of product that can be generated by unit of substrate







Y
P

=



PRODUCTION






RATE
PRODUCT



COMSUMPTION






RATE
SUBSTRATE





[


MMOL





PRODUCT


MMOL





SUBSTRATE


]








    • 2. Substrate-specific Productivity SSP: Product Yield per unit substrate multiplied by the growth rate









SSP
=



Y
P

·
GROWTH







RATE


[


MMOL





PRODUCT


MMOL






SUBSTRATE
·
HR



]







For selected knock-out mutants, the overall flux distribution was calculated by the MOMA approach at which the allowable flux through each nominated reaction is set to zero. Finally the main reaction fluxes (flux threshold=1e−06) are mapped onto the network map using the VANTED add-on FluxMap.


EXAMPLE 7
Enhanced Production of Lysine in Rice Seeds

The essential amino acid lysine (chemical formula: C6H14N2O2) belongs to the group of alkaline amino acids such as arginine and histidine. It is synthesized from aspartate through a linear biochemical pathway of 9 enzymes occurring in the plastid. The energy requirements as well as other biochemical intermediates as detailed in Table 6 are required for production of one molecule lysine.









TABLE 6







Biochemical requirements for synthesis of one molecule lysine.


Referring to the net reaction of the synthesis of one molecule lysine,


the listed substrates and products are required and accordingly


provided for other metabolic processes.











Functional group
Substrates
Products







Precursors
L-aspartate





Pyruvate



Energy metabolites
ATP
ADP + P




2 NADPH
2 NADP+ + H+



Other biochemical
Succinyl-CoA
CoA



intermediates
L-glutarate
2-oxoglutarate





Succinate + CO2










From a modeling point of view, the construction of knock-out mutants of rice seeds with increased lysine content needs the respective precursors, energy sources and the other required biochemical intermediates in a higher extent in comparison to the wild type. In addition, the accumulation of these lysine relevant biochemical intermediates has to be channeled to the synthesis of lysine by knock-out of key metabolic reactions. Different simulations of Growth-coupled Design deliver a list of several knock-out mutants that are defined by a list of metabolic reactions whose knock-out lead to an increased lysine content while minimal biomass accumulation is ensured. These mutants can be further characterized by their exchange flux values as well as their respective flux distributions. Applying the MOMA approach to each knock-out mutant the overall flux distribution including the exchange flux values is obtained.


Referring to the ‘Substrate-specific Productivity’ as ranking criterion, the 4 best knock-out mutants for enhanced lysine content are selected for further analysis (see Table 7). In that case, the 4 best knock-out mutants were obtained from OptKnock and RobustKnock, the both bilevel optimization algorithms. OptGene has also found several knock-out mutants but with a lower SSP value in comparison to the shown knock-out mutants from the other two algorithmic approaches.









TABLE 7







Exchange reaction rates for different lysine mutants


All exchange reactions for 4 selected lysine mutants are shown. Flux values of all


exchange reactions (except biomass reaction) are given by mmol gDW1 h−1;


biomass flux rate is given by hr−1. The name of each mutant is a concatenation


of (1) essential amino acid, (2) number of knock-outs and (3) the used algorithmic


approach of Growth-coupled Design. Abbreviations: Lys—lysine; KO—knock-out;


OK—OptKnock; RK—RobustKnock; SSP—Substrate-specific Productivity.












Exchange
Wild type
Lys-2KO-OK
Lys-3KO-OK
Lys-4KO-OK
Lys-2KO-RK















Uptake







Sucrose
0.0144
0.0144
0.0144
0.0144
0.0144


O2
0.0117
0.0104
0.0108
0.0103
0.0


H2S
0.0002
0.0001
0.0001
0.0001
0.0001


Asparagine
0.0
0.0040
0.0
0.0028
0.0073


Glutamine
0.0024
0.0021
0.0058
0.0037
0.0


Secretion


Biomass
0.0049
0.0019
0.0019
0.0019
0.0019


CO2
0.0168
0.0296
0.0288
0.0297
0.0246


Lactate
0.0
0.0185
0.0199
0.0187
0.0182


Ethanol
0.0
0.0080
0.0092
0.0081
0.0094


Lysine
0.0
0.0052
0.0049
0.0056
0.0064


SSP

6.86e−04
6.46e−04
7.39e−04
8.44e−04


Ranking

3.
4.
2.
1.









The exchange flux values of a mutant as a first measure describes the similarity of the model borders between knock-out mutant and wild type. Except the sucrose uptake and the minimal biomass threshold which is fixed in all simulations, the remaining exchange flux values vary between the wild type and the different mutants. Oxygen uptake is decreased in all mutants compared to the wild type which in turn activates the fermentation process by producing lactate and ethanol. The uptake fluxes of both nitrogen sources asparagine and glutamine is varied a lot between the different mutants. Two of them (Lys-2KO-OK and Lys-4KO-OK) need both amino acids while the other two mutants just need one of them in order to ensure sufficient nitrogen availability for the metabolic processes. The high amount of produced CO2 which is doubled compared to the wild type, is not surprising due to the fact that CO2 is a by-product of lysine synthesis (see Table 6).


A more comprehensive understanding of the different knock-out mutants can be achieved by generating the corresponding flux maps of each mutant. These maps contain all internal reaction fluxes in addition to the exchange fluxes (see Table 4). The flux value is indicated by width of the reaction arrow, i.e. a high reaction flux value is represented as a thick reaction arrow and vice versa. In the following the flux distribution maps are shown for two selected mutants: Lys2KO-RK and Lys-3KO-OK (see FIG. 2). Referring to the exchange fluxes, these two mutants are very different from each other with respect to their oxygen uptake and their used nitrogen source. Table 8 highlights for each mutant the metabolic reactions whose knock-out was predicted by the respective algorithms of Growth-coupled Design.









TABLE 8





Details for Lys-2KO-RK and Lys-3KO-OK.


These two knock-out mutants are characterized by a number of metabolic


reactions whose knock-out lead to an increase in lysine content in rice


seed metabolism. The metabolic reactions are given by their common


names, EC numbers and their corresponding reaction stoichiometry.







Lys-2KO-RK










1
Phosphoglycerate kinase
EC
13BPG[c] + ADP[c] <==>




2.7.2.3
3PG[c] + ATP[c]


2
Cytochrome-c oxidase
EC
QH2[m] + 0.5 O2[m] ==>




1.9.3.1
Q[m] + 2 H[m]







Lys-3KO-OK










1
NAD+-dependent aldehyde
EC
AcAl[c] + NAD+[c] ==>



dehydrogenase
1.2.1.3
AcA[c] + NADH[c]


2
Fructose-1,6-bisphosphatase
EC
F16BP[c] ==> F6P[c] +




3.1.3.11
P[c]


3
Asparagine uptake

==>Asn[c]









By comparing both flux distribution maps, some main differences of flux channeling can be observed. At first, main carbon flux enters the rice seed via the sucrose transporter and is channeled through the sucrose breakdown pathway in both mutants. From there, one portion of the flux is directed to synthesis of ADP-glucose which is transported into the plastid and is the main precursor of starch. The other portion of the main flux enters the glycolysis which produces pyruvate, an important precursor of lysine, in the end. While the Lys-2KO-RK mutant uses the cytosolic as well as the plastidic part of glycolysis to produce pyruvate, the Lys-3KO-RK mutant uses the plastidic part in a higher extent. In addition, many transporters of glycolytic intermediates between cytosol and plastid are very active in both mutants (not shown in the flux maps). The full amount of produced pyruvate cannot be used solely for lysine synthesis, that's why a great portion is used for production of the fermentative metabolites lactate and ethanol. The other important precursor of lysine is aspartate which is directly synthesized from affiliated asparagine in Lys-2KO-RK, while in the other mutant it is generated from the affiliated glutamine by consuming energy in the form of ATP. Another difference between both flux maps is the flux through the TCA cycle which is actually no ‘real’ cycle in the Lys-2KO-RK mutant. The main function of the TCA cycle in this mutant is the remobilization of NADH from NAD which is used during the production of the fermentative products. The other mutant uses the glycolytic enzyme phosphoglycerate kinase (knock-out reaction in Lys-2KO-RK) for remobilization of NADH, and the TCA cycle shows a minimal cycling flux. Furthermore, the metabolic processes of Lys-3KO-OK require a lot of energy due to the high flux activity of oxidative phosphorylation pathway. In the other mutant, the oxidative phosphorylation is knocked-out by the enzyme cytochrome-c oxidase. However, the Lys-2KO-RK is able to synthesize more lysine from the same amount of sucrose using less energy resources in comparison to Lys-3KO-OK


REFERENCES
Examples Section



  • Burgard A. P., Pharkya P., Maranas C. D. (2003) OptKnock: A bilevel programming framework for identifying gene knockout strategies for microbial strain optimization. Biotechnology and Bioengineering. 84, 647-657

  • Feist A. M., Zielinski D. C., Orth J. D., Schellenberger J., Herrgard M. J., Palsson B. O. (2010) Model-driven evaluation of the production potential for growth-coupled products of Escherichia coli. Metabolic Engineering. 12, 173-186

  • Furbank R. T., Scofield G. N., Hirose T., Wang X. D., Patrick J. W., Offler C. E. (2001) Cellular localization and function of a sucrose transporter OsSUT1 in developing rice grains. Australian Journal of Plant Physiology. 28, 1187-1196

  • Grafahrend-Belau E., Schreiber F., Koschützki D., Junker B. H. (2009) Flux balance analysis of barley seeds: a computational approach to study systemic properties of central metabolism. Plant Physiology. 149, 585-598

  • Hucka M., Finney A., Sauro H. M., Bolouri H., Doyle J. C., Kitano H. (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics. 19, 524-531

  • Lun D. S., Rockwell G., Guido N. J., Baym M., Kelner J. A., Berger B., Galagan J. E., Church G. M. (2009) Large-scale identification of genetic design strategies using local search. Molecular systems biology. 5, 296

  • Patil K. R., Rocha I., Förster J., Nielsen J. (2005) Evolutionary programming as a platform for in silico metabolic engineering. BMC Bioinformatics. 6, 308

  • Pharkya P., Maranas C. D. (2006) An optimization framework for identifying reaction activation/inhibition or elimination candidates for overproduction in microbial systems. Metabolic Engineering. 8(1), 1-13

  • Ranganathan S., Suthers P. F., Maranas C. D. (2010) OptForce: An optimization procedure for identifying all genetic manipulations leading to targeted overproductions. PLoS Computational Biology. 6, e1000744

  • Savinell J. M., Palsson B. O. (1992) Network analysis of intermediary metabolism using linear optimization: 1. Development of mathematical formalism. Journal of Theoretical Biology. 154, 421-454

  • Schellenberger J., Que R., Fleming R. M. T., Thiele I., Orth J. D., Feist A. M., Zielinski D. C., Bordbar A., Lewis N. E., Rahmanian S., Kang J., Hyduke D. R., Palsson B. O. (2011) Quantitative prediction of cellular metabolism with constraint-based models: the COBRA toolbox v2.0. Nature Protocols. 6, 1290-1307

  • Segre D., Vitkup D., Church G. M. (2002) Analysis of optimality in natural and perturbed metabolic networks. PNAS. 99, 15112-15117

  • Shlomi T., Berkman O., Ruppin E. (2005) Regulatory on/off minimization of metabolic flux changes after genetic perturbations. PNAS. 102, 7695-7700

  • Tepper N. and Shlomi T. (2010) Predicting metabolic engineering knockout strategies for chemical production: accounting for competing pathways. Bioinformatics. 26, 536-543

  • Yang L., Cluett W. R., Mahadevan R. (2011) EMILiO: A fast algorithm for genome-scale strain design. Metabolic Engineering. 13(3), 272-281










TABLE 2







growth-coupled design approaches














Predictions





Name
Type
for
Availability
Comments
Reference





OptKnock
BO
KO
COBRA toolbox
Prediction of gene deletion strategies leading to
Burgard et al. (2003) Biotechnology






overproduction of chemicals of interest
and Bioengineering. 84(6): 647-657


RobustKnock
BO
KO
Matlab script
Prediction of gene deletion strategies leading to
Tepper and Shlomi (2010)






overproduction of chemicals of interest, by
Bioinformatics. 26(4): 536-543






accounting for the presence of competing pathways






in the network model


OptGene
HA
KO
COBRA toolbox/
Identification of gene deletion strategies for
Patil et al. (2005) BMC





OptFlux
optimization of a desired phenotypic objective
Bioinformatics. 6: 308






function (linear + non-linear)


OptForce
BO
KD/KO
none
Identification of possible engineering interventions
Ranganathan et al. (2010) PLoS




and OEX

by classifying reactions whether their flux values
Computational Biology. 6(4):






must increase, decrease or become equal to 0 to meet
e1000744






a pre-specified overproduction target


EMILiO
BO
KD/KO
none
(1) Identification of a subset of reactions with the
Yang et al. (2011) Metabolic




and OEX

potential to improve growth-coupled biochemical
Engineering. 13(3): 272-281






production if their fluxes are optimized and (2)






quantitatively predict the optimal flux ranges that






maximize production


OptReg
BO
KD/KO
none
Extension to OptKnock allowing for up and/or down-
Pharkya and Maranas (2006)




and OEX

regulation in addition to gene eliminations to meet
Metabolic Engineering. 8: 1-13






a bioproduction goal


GDLS
HA
KO
COBRA toolbox
local search approach with multiple search paths to
Lun et al. (2009) Molecular






find a set of locally optimal genetic strategies for
Systems Biology. 5: 296






knock-out mutants
















TABLE 3







metabolic conversion steps of the rice model. Letters in parentheses relate to the allocation of


a metabolite to a specific cell compartiment; [c] = cytosol, [m] = mitochondrion, [p] = plastid













Rxn








name
Rxn description
Formula
Subsystem
Reversible
LB
UB
















R955
dihydroxy-acid
DIV[p] ==> OIV[p]
Valine Leucine
0
0
1000



dehydratase (valin

Isoleucine



synthesis)

Biosynthesis


R933
aspartate-semialdehyde
AspSA[p] + NADP[p] + P[p] <==>
Glycine Serine
1
−1000
1000



dehydrogenase
NADPH[p] + PAsp[p]
Threonine





Metabolism


R852
citrate synthase
AcCoA[m] + OAA[m] ==> Cit[m] + CoA[m]
TCA Cycle
0
0
1000


R1020
LeuSPONTANEOUS
IPO[p] ==> CO2[p] + OIC[p]
Valine Leucine
0
0
1000





Isoleucine





Biosynthesis


R915
imidazoleglycerol-
Gln[p] + PRu_AICARP[p] ==> AICAR[p] +
Histidine Metabolism
0
0
1000



phosphate synthase
Glu[p] + IGP[p]


R897
transaldolase
GAP[p] + S7P[p] <==> E4P[p] + F6P[p]
Pentose Phosphate
1
−1000
1000





Pathway


R820
aldehyde dehydrogenase
AcAI[c] + NAD[c] ==> AcA[c] + NADH[c]
Glycolysis
0
0
1000



(NAD+) (cALDH)

Gluconeogenesis


R883
inorganic diphosphatase
PP[p] ==> 2 P[p]
Oxidative
0
0
1000





Phosphorylation


R799
diphosphate-fructose-6-
F6P[c] + PP[c] <==> F16P[c] + P[c]
Fructose Mannose
1
−1000
1000



phosphate 1-

Metabolism



phosphotransferase


R805
phosphopyruvate
2PG[c] <==> PEP[c]
Glycolysis
1
−1000
1000



hydratase (cENOLASE)

Gluconeogenesis


R797
phosphoglucose
F6P[c] <==> G6P[c]
Glycolysis
1
−1000
1000



isomerase (cPGI)

Gluconeogenesis


R899
3-deoxy-7-
E4P[p] + PEP[p] ==> DAH7P[p] + P[p]
Phenylalanine
0
0
1000



phosphoheptulonate

Tyrosine Tryptophan



synthase

Biosynthesis


R825
alanine transaminase
2OG[c] + Ala[c] <==> Glu[c] + Pyr[c]
Alanine Aspartate
1
−1000
1000





Glutamate Metabolism


R925
amino-acid N-
AcCoA[p] + Glu[p] ==> AcGlu[p] + CoA[p]
Arginine Proline
0
0
1000



acetyltransferase

Metabolism


R930
ornithine
CP[p] + Or[p] <==> Citru[p] + P[p]
Arginine Proline
1
−1000
1000



carbamoyltransferase

Metabolism


R876
glyceraldehyde-3-
GAP[p] + NADP[p] + P[p] <==> 13BPG[p] +
Glycolysis
1
−1000
1000



phosphate
NADPH[p]
Gluconeogenesis



dehydrogenase (NADP+)



(phosph.)


R965
serine O-
AcCoA[p] + Ser[p] ==> AcSer[p] + CoA[p]
Cysteine Methionine
0
0
1000



acetyltransferase

Metabolism


R796
phosphoglucomutase
G1P[c] <==> G6P[c]
Glycolysis
1
−1000
1000



(cPGM)

Gluconeogenesis


R957
2-isopropylmalate
AcCoA[p] + OIV[p] ==> 2IPM[p] + CoA[p]
Valine Leucine
0
0
1000



synthase

Isoleucine





Biosynthesis


R919
histidinol dehydrogenase
Hol[p] + 2 NAD[p] ==> His[p] + 2 NADH[p]
Histidine Metabolism
0
0
1000


R823
asparagine synthase
ATP[c] + Asp[c] + Gln[c] ==> AMP[c] +
Alanine Aspartate
0
0
1000



(glutamine-hydrolysing)
Asn[c] + Glu[c] + PP[c]
Glutamate Metabolism


R913
phosphoribosyl-AMP
PR_AMP[p] ==> PR_AICARP[p]
Histidine Metabolism
0
0
1000



cyclohydrolase


R874
fructose-bisphosphate
F16P[p] <==> DHAP[p] + GAP[p]
Glycolysis
1
−1000
1000



aldolase (pALD)

Gluconeogenesis


R875
triose phosphate
DHAP[p] <==> GAP[p]
Glycolysis
1
−1000
1000



isomerase (pTIM)

Gluconeogenesis


R928
acetylornithine
2OG[p] + AcOr[p] <==> AcGluSA[p] + Glu[p]
Lysine Biosynthesis
1
−1000
1000



transaminase


R943
2,3,4,5-
SuccCoA[p] + THDPA[p] ==> CoA[p] +
Lysine Biosynthesis
0
0
1000



tetrahydropyridine-2,6-
SuccAH[p]



dicarboxylate N-



succinyltransferase


R964
glycine hydroxymethyl-
Gly[p] + METTHF[p] <==> Ser[p] + THF[p]
Glycine Serine
1
−1000
1000



transferase (pSHMT)

Threonine Metabolism


R923
pyrroline-5-carboxylate
NADH[p] + PyrrC[p] <==> NAD[p] + Pro[p]
Arginine Proline
1
−1000
1000



reductase

Metabolism


R973
acetate-CoA ligase
ATP[p] + AcA[p] + CoA[p] ==> AMP[p] +
Glycolysis
0
0
1000




AcCoA[p] + PP[p]
Gluconeogenesis


R892
phosphogluconate
6PG[p] + NADP[p] ==> CO2[p] +
Pentose Phosphate
0
0
1000



dehydrogenase
NADPH[p] + Ru5P[p]
Pathway



(decarboxylating)



(p6-PGDH)


R888
alpha-glucosidase
Malt[p] ==> 2Glc[p]
Galactose Metabolism
0
0
1000


R803
phosphoglycerate kinase
13BPG[c] + ADP[c] <==> 3PG[c] + ATP[c]
Glycolysis
1
−1000
1000



(cPGlyK)

Gluconeogenesis


R798
6-phosphofructokinase
ATP[c] + F6P[c] ==> ADP[c] + F16P[c]
Glycolysis
0
0
1000



(cPFK)

Gluconeogensis


R801
triose phosphate
DHAP[c] <==> GAP[c]
Glycolysis
1
−1000
1000



isomerase (cTIM)

Gluconeogenesis


R922
pyrroline-5-carboxylate
ATP[p] + Glu[p] + NADPH[p] ==> ADP[p] +
Arginine Proline
0
0
1000



synthase
GluSA[p] + NADP[p] + P[p]
Metabolism


R920
glutamate dehydrogenase
Glu[p] + NADP[p] <==> 2OG[p] +
Alanine Aspartate
1
−1000
1000



(NAD(P))
NADPH[p] + NH3[p]
Glutamate Metabolism


R927
N-acetyl-gamma-
AcGluSA[p] + NADP[p] + P[p] <==>
Arginine Proline
1
−1000
1000



glutamyl-phosphate
AcGluP[p] + NADPH[p]
Metabolism



reductase


R907
aromatic-amino-acid
2OG[p] + Agn[p] <==> Glu[p] + PRE[p]
Phenylalanine
1
−1000
1000



transaminase

Tyrosine Tryptophan



(prephenate

Biosynthesis



aminotransferase)


R809
sucrose synthase
UDP[c] + sucrose[c] <==> Frc[c] +
Starch Sucrose
1
−1000
1000




UDPGlc[c]
Metabolism


R949
acetolactate synthase
2OB[p] + Pyr[p] ==> 2AHB[p] + CO2[p]
Valine Leucine
0
0
1000



(isoleucine synthesis)

Isoleucine





Biosynthesis


R929
aminoacylase
AcOr[p] ==> AcA[p] + Or[p]
Arginine Proline
0
0
1000





Metabolism


R959
3-isopropylmalate
3IPM[p] + NAD[p] ==> IPO[p] + NADH[p]
Valine Leucine
0
0
1000



dehydrogenase

Isoleucine





Biosynthesis


R884
ADPglucose
ATP[p] + G1P[p] <==> ADPglc[p] + PP[p]
Starch Sucrose
1
−1000
1000



pyrophosphorylase

Metabolism



(pAGPase)


R811
sucrose phosphate
F6P[c] + UDPGlc[c] <==> S6P[c] + UDP[c]
Starch Sucrose
1
−1000
1000



synthase

Metabolism


R937
cystathionine gamma-
Cys[p] + PHOMOSer[p] ==> CysTh[p] + P[p]
Cysteine Methionine
0
0
1000



synthase

Metabolism


R835
argininosuccinate lyase
ArgSucc[c] <==> Arg[c] + Fum[c]
Alanine Aspartate
1
−1000
1000





Glutamate Metabolism


R900
3-dehydroquinate
DAH7P[p] ==> 3DHQ[p] + P[p]
Phenylalanine
0
0
1000



synthase

Tyrosine Tryptophan





Biosynthesis


R902
shikimate
NADP[p] + Sh[p] <==> 3DSh[p] + NADPH[p]
Phenylalanine
1
−1000
1000



dehydrogenase

Tyrosine Tryptophan





Biosynthesis


R950
ketol-acid
2AHB[p] + NADPH[p] ==> DMV[p] +
Valine Leucine
0
0
1000



reductoisomerase
NADP[p]
Isoleucine



(isoleucine

Biosynthesis



synthesis)


R901
3-dehydroquinate
3DHQ[p] <==> 3DSh[p]
Phenylalanine
1
−1000
1000



dehydratase

Tyrosine Tryptophan





Biosynthesis


R859
fumarate hydratase
Mal[m] <==> Fum[m]
TCA Cycle
1
−1000
1000


R944
succinyldiaminopimelate
2OG[p] + SuccDAH[p] <==> Glu[p] +
Lysine Biosynthesis
1
−1000
1000



transaminase
SuccAH[p]


R932
aspartate kinase
ATP[p] + Asp[p] <==> ADP[p] + PAsp[p]
Glycine Serine
1
−1000
1000





Threonine Metabolism


R946
Diaminopimelate
DAH[p] <==> mDAH[p]
Lysine Biosynthesis
1
−1000
1000



epimerase


R885
starch synthase (simpl.)
ADPglc[p] ==> ADP[p] + starch[p]
Starch Sucrose
0
0
1000





Metabolism


R958
3-isopropylmalate
3IPM[p] <==> 2IPM[p]
Valine Leucine
1
−1000
1000



dehydratase

Isoleucine





Biosynthesis


R880
pyruvate kinase (pPK)
ADP[p] + PEP[p] ==> ATP[p] + Pyr[p]
Glycolysis
0
0
1000





Gluconeogenesis


R891
6-
GL6P[p] ==> 6PG[p]
Pentose Phosphate
0
0
1000



phosphogluconolactonase

Pathway


R810
sucrose phosphate
S6P[c] ==> P[c] + sucrose[c]
Starch Sucrose
0
0
1000



phosphatase

Metabolism


R802
glyceraldehyde-3-
GAP[c] + NAD[c] + P[c] <==> 13BPG[c] +
Glycolysis
1
−1000
1000



phosphate dehydrogenase
NADH[c]
Gluconeogenesis



(phosph.)


R812
hexokinase
ATP[c] + Glc[c] ==> ADP[c] + G6P[c]
Glycolysis
0
0
1000





Gluconeogenesis


R893
ribulose-phosphate
Ru5P[p] <==> X5P[p]
Pentose Phosphate
1
−1000
1000



3-epimerase

Pathway



(pRuPepimerase)


R861
glutamate dehydrogenase
Glu[m] + NAD[m] <==> 2OG[m] + NADH[m] +
Alanine Aspartate
1
−1000
1000




NH3[m]
Glutamate Metabolism


R947
Diaminopimelate
mDAH[p] ==> CO2[p] + Lys[p]
Lysine Biosynthesis
0
0
1000



decarboxylase


R853
aconitate hydratase
Cit[m] <==> Icit[m]
TCA Cycle
1
−1000
1000



(mACO)


R833
glyceraldehyde-3-
GAP[c] + NADP[c] ==> 3PG[c] + NADPH[c]
Glycolysis
0
0
1000



phosphate dehydrogenase

Gluconeogenesis



(NADP)


R894
ribose-5-phosphate
R5P[p] <==> Ru5P[p]
Pentose Phosphate
1
−1000
1000



isomerase (pR5P

Pathway



isomerase)


R963
phosphoserine phosphatase
Pser[p] ==> P[p] + Ser[p]
Glycine Serine
0
0
1000





Threonine Metabolism


R824
asparaginase
Asn[c] ==> Asp[c] + NH3[c]
Alanine Aspartate
0
0
1000





Glutamate Metabolism


R966
cysteine synthase
AcSer[p] + H2S[p] ==> AcA[p] + Cys[p]
Cysteine Methionine
0
0
1000





Metabolism


R917
histidinol-phosphate
Glu[p] + IAP[p] ==> 2OG[p] + HolP[p]
Histidine Metabolism
0
0
1000



transaminase


R829
isocitrate dehydrogenase
Icit[c] + NADP[c] <==> 2OG[c] + CO2[c] +
TCA Cycle
1
−1000
1000



(NADP+)(cICDH)
NADPH[c]


R961
phosphoglycerate
3PG[p] + NAD[p] ==> NADH[p] + PHPyr[p]
Glycine Serine
0
0
1000



dehydrogenase

Threonine Metabolism


R872
phosphoglucose isomerase
F6P[p] <==> G6P[p]
Glycolysis
1
−1000
1000



(pPGI)

Gluconeogenesis


R854
isocitrate dehydrogenase
Icit[m] + NADP[m] <==> 2OG[m] + CO2[m] +
TCA Cycle
1
−1000
1000



(NADP+)(mICDH)
NADPH[m]


R938
cystathionine beta-lyase
CysTh[p] ==> HOMOCys[p] + NH3[p] +
Cysteine Methionine
0
0
1000




Pyr[p]
Metabolism


R814
UDPglucose
G1P[c] + UTP[c] <==> PP[c] + UDPGlc[c]
Starch Sucrose
1
−1000
1000



pyrophosphorylase

Metabolism


R908
arogenate dehydrogenase
Agn[p] + NAD[p] ==> CO2[p] + NADH[p] +
Phenylalanine
0
0
1000




Tyr[p]
Tyrosine Tryptophan





Biosynthesis


R890
glucose-6-phosphate
G6P[p] + NADP[p] <==> GL6P[p] +
Pentose Phosphate
1
−1000
1000



dehydrogenase (p2-
NADPH[p]
Pathway



G6PDH)


R895
transketolase
GAP[p] + S7P[p] <==> R5P[p] + X5P[p]
Pentose Phosphate
1
−1000
1000



(sedoheptulose 7-P -

Pathway



ribose 5-P)


R918
histidinol-phosphatase
HolP[p] ==> Hol[p] + P[p]
Histidine Metabolism
0
0
1000


R905
chorismate synthase
EPSP[p] ==> Ch[p] + P[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R954
ketol-acid
AcLac[p] + NADPH[p] ==> DIV[p] + NADP[p]
Valine Leucine
0
0
1000



reductoisomerase

Isoleucine



(valin synthesis)

Biosynthesis


R800
fructose-bisphosphate
F16P[c] <==> DHAP[c] + GAP[c]
Glycolysis
1
−1000
1000



aldolase (cALD)

Gluconeogenesis


R822
glutamate-ammonia
ATP[c] + Glu[c] + NH3[c] ==> ADP[c] +
Alanine Aspartate
0
0
1000



ligase (cGS, GSI)
Gln[c] + P[c]
Glutamate Metabolism


R975
glutamate synthase
2OG[p] + Gln[p] + NADH[p] ==> 2 Glu[p] +
Alanine Aspartate
0
0
1000



(NADH)
NAD[p]
Glutamate Metabolism


R974
Proline biosynthesis:
GluSA[p] ==> PyrrC[p]
Arginine Proline
0
0
1000



glutamate 5-

Metabolism



semialdehyde-1-



pyrroline-5-carboxylate



(spontaneous reaction)


R926
acetylglutamate kinase
ATP[p] + AcGlu[p] ==> ADP[p] + AcGluP[p]
Arginine Proline
0
0
1000





Metabolism


R806
pyruvate kinase (cPK)
ADP[c] + PEP[c] ==> ATP[c] + Pyr[c]
Glycolysis
0
0
1000





Gluconeogenesis


R858
succinate dehydrogenase
Q[m] + Succ[m] <==> Fum[m] + QH2[m]
TCA Cycle
1
−1000
1000



(ubiquinone)


R906
chorismate mutase
Ch[p] ==> PRE[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R813
fructokinase
ATP[c] + Frc[c] ==> ADP[c] + F6P[c]
Fructose Mannose
0
0
1000





Metabolism


R857
succinate-CoA ligase
ATP[m] + CoA[m] + Succ[m] <==> ADP[m] +
TCA Cycle
1
−1000
1000



(ADP-forming)
P[m] + SuccCoA[m]


R952
branched-chain-amino-
2OG[p] + Ile[p] <==> Glu[p] + OMV[p]
Valine Leucine
1
−1000
1000



acid transaminase

Isoleucine



(isoleucine synthesis)

Biosynthesis


R889
adenylate kinase (pAdK)
AMP[p] + ATP[p] <==> 2 ADP[p]
Purine Metabolism
1
−1000
1000


R904
3-phosphoshikimate 1-
PEP[p] + Sh3P[p] <==> EPSP[p] + P[p]
Phenylalanine
1
−1000
1000



carboxyvinyltransferase

Tyrosine Tryptophan





Biosynthesis


R830
malate dehydrogenase
Mal[c] + NAD[c] <==> NADH[c] + OAA[c]
TCA Cycle
1
−1000
1000



(cMalDH)


R816
nucleoside-diphosphate
ATP[c] + UDP[c] <==> ADP[c] + UTP[c]
Purine Metabolism
1
−1000
1000



kinase (cNDPkin: UDP)


R909
arogenate dehydratase
Agn[p] ==> CO2[p] + Phe[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R819
lactate dehydrogenase
Lac[c] + NAD[c] <==> NADH[c] + Pyr[c]
Glycolysis
1
−1000
1000





Gluconeogenesis


R936
threonine synthase
PHOMOSer[p] ==> P[p] + Thr[p]
Glycine Serine
0
0
1000





Threonine Metabolism


R834
argininosuccinate
ATP[c] + Asp[c] + Citru[c] <==> AMP[c] +
Alanine Aspartate
1
−1000
1000



synthase
ArgSucc[c] + PP[c]
Glutamate Metabolism


R951
dihydroxy-acid dehydratase
DMV[p] ==> OMV[p]
Valine Leucine
0
0
1000



(isoleucine synthesis)

Isoleucine





Biosynthesis


R856
oxoglutarate
2OG[m] + CoA[m] + NAD[m] ==> CO2[m] +
TCA Cycle
0
0
1000



dehydrogenase (succinyl-
NADH[m] + SuccCoA[m]



transferring)


R914
1-(5-phosphoribosyl)-5-
PR_AICARP[p] ==> PRu_AICARP[p]
Histidine Metabolism
0
0
1000



((5-phosphoribosyl-



amino)methylidene-



amino)imid azole-4-carboxamide



isomerase


R953
acetolactate synthase
2 Pyr[p] ==> AcLac[p] + CO2[p]
Valine Leucine
0
0
1000



(valin synthesis)

Isoleucine





Biosynthesis


R873
6-phosphofructokinase
ATP[p] + F6P[p] ==> ADP[p] + F16P[p]
Glycolysis
0
0
1000



(pPFK)

Gluconeogenesis


R862
aspartate transaminase
2OG[m] + Asp[m] <==> Glu[m] + OAA[m]
Alanine Aspartate
1
−1000
1000



(mAAT)

Glutamate Metabolism


R863
malate dehydrogenase
Mal[m] + NAD[m] ==> CO2[m] + NADH[m] +
Pyruvate Metabolism
0
0
1000



(decarboxylating)
Pyr[m]


R896
transketolase (fructose
F6P[p] + GAP[p] <==> E4P[p] + X5P[p]
Pentose Phosphate
1
−1000
1000



6-P - erythrose 4-P)

Pathway


R912
phosphoribosyl-ATP
PR_ATP[p] ==> PP[p] + PR_AMP[p]
Histidine Metabolism
0
0
1000



diphosphatase


R821
aspartate transaminase
2OG[c] + Asp[c] <==> Glu[c] + OAA[c]
Alanine Aspartate
1
−1000
1000



(cAAT)

Glutamate Metabolism


R851
pyruvate dehydrogenase
CoA[m] + NAD[m] + Pyr[m] ==> AcCoA[m] +
Glycolysis
0
0
1000



complex (mPyrDH)
CO2[m] + NADH[m]
Gluconeogenesis


R804
phosphoglycerate mutase
3PG[c] <==> 2PG[c]
Glycolysis
1
−1000
1000



(cPGlyM)

Gluconeogenesis


R931
carbamoyl-phosphate
2 ATP[p] + CO2[p] + Gln[p] ==> 2 ADP[p] +
Arginine Proline
0
0
1000



synthase (glutamine-
CP[p] + Glu[p] + P[p]
Metabolism



hydrolysing)


R832
phosphoenolpyruvate
ATP[c] + OAA[c] ==> ADP[c] + CO2[c] +
Glycolysis
0
0
1000



carboxykinase (ATP)
PEP[c]
Gluconeogenesis


R878
phosphoglycerate mutase
3PG[p] <==> 2PG[p]
Glycolysis
1
−1000
1000



(pPGlyM)

Gluconeogenesis


R934
homoserine
HOMOSer[p] + NAD[p] <==> AspSA[p] +
Glycine Serine
1
−1000
1000



dehydrogenase
NADH[p]
Threonine Metabolism


R910
ribose-phosphate
ATP[p] + R5P[p] <==> AMP[p] + PRPP[p]
Pentose Phosphate
1
−1000
1000



diphosphokinase

Pathway



(pPRPPS)


R817
pyruvate decarboxylase
Pyr[c] ==> AcAl[c] + CO2[c]
Glycolysis
0
0
1000





Gluconeogenesis


R911
ATP phosphoribosyl-
ATP[p] + PRPP[p] ==> PP[p] + PR_ATP[p]
Histidine Metabolism
0
0
1000



transferase


R815
ADPglucose
ATP[c] + G1P[c] <==> ADPglc[c] + PP[c]
Starch Sucrose
1
−1000
1000



pyrophosphorylase

Metabolism



(cAGPase)


R871
phosphoglucomutase
G1P[p] <==> G6P[p]
Glycolysis
1
−1000
1000



(pPGM)

Gluconeogenesis


R831
phosphoenolpyruvate
CO2[c] + PEP[c] ==> OAA[c] + P[c]
Pyruvate Metabolism
0
0
1000



carboxylase


R860
malate dehydrogenase
Mal[m] + NAD[m] <==> NADH[m] + OAA[m]
TCA Cycle
1
−1000
1000



(mMalDH)


R879
phosphopyruvate hydratase
2PG[p] <==> PEP[p]
Glycolysis
1
−1000
1000



(pENOLASE)

Gluconeogenesis


R887
beta-amylase (modell)
2 starch[p] ==> Malt[p]
Starch Sucrose
0
0
1000





Metabolism


R877
phosphoglycerate kinase
13BPG[p] + ADP[p] <==> 3PG[p] + ATP[p]
Glycolysis
1
−1000
1000



(pPGlyK)

Gluconeogenesis


R886
alpha-amylase (modell)
3 starch[p] ==> Glc[p] + Malt[p]
Starch Sucrose
0
0
1000





Metabolism


R945
succinyl-diaminopimelate
SuccDAH[p] ==> DAH[p] + Succ[p]
Lysine Biosynthesis
0
0
1000



desuccinylase


R818
alcohol dehydrogenase
Eth[c] + NAD[c] <==> AcAl[c] + NADH[c]
Glycolysis
1
−1000
1000





Gluconeogensis


R903
shikimate kinase
ATP[p] + Sh[p] ==> ADP[p] + Sh3P[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R916
imidazoleglycerol-
IGP[p] ==> IAP[p]
Histidine Metabolism
0
0
1000



phosphate dehydratase


R942
dihydrodipicolinate
NADP[p] + THDPA[p] <==> DPA[p] +
Lysine Biosynthesis
1
−1000
1000



reductase
NADPH[p]


R935
homoserine kinase
ATP[p] + HOMOSer[p] ==> ADP[p] +
Glycine Serine
0
0
1000




PHOMOSer[p]
Threonine Metabolism


R956
branched-chain-amino-
2OG[p] + Val[p] <==> Glu[p] + OIV[p]
Valine Leucine
1
−1000
1000



acid transaminase

Isoleucine



(valine synthesis)

Biosynthesis


R827
adenylate kinase (cAdK)
AMP[c] + ATP[c] <==> 2 ADP[c]
Purine Metabolism
1
−1000
1000


R948
threonine ammonia-lyase
Thr[p] ==> 2OB[p] + NH3[p]
Glycine Serine
0
0
1000





Threonine Metabolism


R941
dihydrodipicolinate
AspSA[p] + Pyr[p] ==> DPA[p]
Lysine Biosynthesis
0
0
1000



synthase


R924
ornithine-oxo-acid
2OG[p] + Or[p] <==> GluSA[p] + Glu[p]
Arginine Proline
1
−1000
1000



transaminase

Metabolism


R837
glutamate decarboxylase
Glu[c] ==> CO2[c] + Gaba[c]
Alanine Aspartate
0
0
1000





Glutamate Metabolism


R865
4-aminobutyrate
2OG[m] + Gaba[m] <==> Glu[m] +
Alanine Aspartate
1
−1000
1000



transaminase
SuccSAl[m]
Glutamate Metabolism


R866
succinate-semialdehyde
NADP[m] + SuccSAl[m] ==> NADPH[m] +
Alanine Aspartate
0
0
1000



dehydrogenase
Succ[m]
Glutamate Metabolism



(NAD(P)+)


R881
fructose-1,6-
F16P[p] ==> F6P[p] + P[p]
Glycolysis
0
0
1000



bisphosphatase

Gluconeogenesis



(pFBPase)


R808
pyruvate, phosphate
ATP[c] + P[c] + Pyr[c] <==> AMP[c] +
Pyruvate Metabolism
1
−1000
1000



dikinase (cPPDK)
PEP[c] + PP[c]


R807
fructose-1,6-
F16P[c] ==> F6P[c] + P[c]
Glycolysis
0
0
1000



bisphosphatase

Gluconeogenesis



(cFBPase)


R855
isocitrate dehydrogenase
Icit[m] + NAD[m] <==> 2OG[m] + CO2[m] +
TCA Cycle
1
−1000
1000



(NAD+) (mlCDH)
NADH[m]


R870
H+-exporting ATPase
ADP[m] + 3 Hext + P[m] <==> ATP[m]
Oxidative
1
−1000
1000





Phosphorylation


R962
phosphoserine
Glu[p] + PHPyr[p] ==> 2OG[p] + Pser[p]
Glycine Serine
0
0
1000



transaminase

Threonine Metabolism


R972
malate dehydrogenase
Mal[p] + NADP[p] ==> CO2[p] + NADPH[p] +
Pyruvate Metabolism
0
0
1000



(oxaloacetate-
Pyr[p]



decarboxylating)



(NADP+)


R939
methionine synthase
HOMOCys[p] + MTHF[p] ==> Met[p] +
Cysteine Methionine
0
0
1000



(pMS)
THF[p]
Metabolism


R967
phosphoribosylamino-
AICAR[p] + FTHF[p] <==> PRFICA[p] +
Purine Metabolism
1
−1000
1000



imidazolecarboxamide
THF[p]



formyltransferase


R971
nucleoside-diphosphate
ATP[p] + GDP[p] <==> ADP[p] + GTP[p]
Purine Metabolism
1
−1000
1000



kinase (pNDPkin: GDP)


R969
adenylosuccinate synthase
Asp[p] + GTP[p] + IMP[p] ==> Asuc[p] +
Purine Metabolism
0
0
1000




GDP[p] + P[p]


R968
IMP cyclohydrolase
IMP[p] <==> PRFICA[p]
Purine Metabolism
1
−1000
1000


R970
adenylosuccinate lyase
Asuc[p] <==> AMP[p] + Fum[p]
Purine Metabolism
1
−1000
1000



(AMP)


R845
methenyltetrahydrofolate
METHF[c] <==> FTHF[c]
Folate Metabolism
1
−1000
1000



cyclohydrolase



(cMTHCH)


R847
methylenetetrahydrofolate
METTHF[c] + NADH[c] ==> MTHF[c] +
Folate Metabolism
0
0
1000



reductase (NAD(P)H)
NAD[c]



(cMTFHR)


R846
methylenetetrahydro-
METTHF[c] + NADP[c] <==> METHF[c] +
Folate Metabolism
1
−1000
1000



folate dehydrogenase
NADPH[c]



(NADP+)(cMTHD)


R844
formate-tetrahydrofolate
ATP[c] + For[c] + THF[c] <==> ADP[c] +
Folate Metabolism
1
−1000
1000



ligase (cFTHFS)
FTHF[c] + P[c]


R867
NADH dehydrogenase
NADH[m] + Q[m] ==> 2 Hext + NAD[m] +
Oxidative
0
0
1000



(ubiquinone)
QH2[m]
Phosphorylation


R869
cytochrome-c oxidase
0.5 O2[m] + QH2[m] ==> 2 Hext + Q[m]
Oxidative
0
0
1000





Phosphorylation


R1004
adenosine kinase
ADN[c] + ATP[c] ==> ADP[c] + AMP[c]
Purine Metabolism
0
0
1000


R1009
ATP citrate synthase
ATP[p] + Cit[p] + CoA[p] ==> ADP[p] +
TCA Cycle
0
0
1000




AcCoA[p] + OAA[p] + P[p]


R960
branced-chain-amino-
2OG[p] + Leu[p] <==> Glu[p] + OIC[p]
Valine Leucine
1
−1000
1000



acid transaminase

Isoleucine



(leucine synthesis)

Biosynthesis


R1012
aspartate transaminase
2OG[p] + Asp[p] <==> Glu[p] + OAA[p]
Alanine Aspartate
1
−1000
1000



(pAAT)

Glutamate Metabolism


R1014
glycine hydroxymethyl-
Gly[m] + METTHF[m] <==> Ser[m] + THF[m]
Glycine Serine
1
−1000
1000



transferase (mSHMT)

Threonine Metabolism


R1013
glycine decarboxylase
Gly[m] + NADH[m] + THF[m] <==> CO2[m] +
Folate Metabolism
1
−1000
1000



system
METTHF[m] + NAD[m] + NH3[m]


R1015
glycine hydroxymethyl-
Gly[c] + METTHF[c] <==> Ser[c] + THF[c]
Glycine Serine
1
−1000
1000



transferase (cSHMT)

Threonine Metabolism


R828
aconitate hydratase
Cit[c] <==> Icit[c]
TCA Cycle
1
−1000
1000



(cA-CO)


R848
isocitrate lyase
Icit[c] ==> Glx[c] + Succ[c]
Glyoxylate Cycle
0
0
1000


R850
oxalate decarboxylase
Oxl[c] ==> CO2[c] + For[c]
Formate Metabolism
0
0
1000


R849
glyoxylate oxidase
Glx[c] + O2[c] ==> Oxl[c]
Formate Metabolism
0
0
1000


R742
sucrose transporter
Hext <==> sucrose[c]
Uptake
1
−1000
1000


R746
pyruvate transporter
Pyr[c] <==> Pyr[m]
Internal Transport
1
−1000
1000



(simpl.)


R747
glutamate/aspartate
Asp[m] + Glu[c] <==> Asp[c] + Glu[m]
Internal Transport
1
−1000
1000



transporter


R769
ADP-glucose transporter
ADP[p] + ADPglc[c] <==> ADP[c] +
Internal Transport
1
−1000
1000



(AMP)
ADPglc[p]


R743
AA transporter
Hext <==> Asn[c]
Uptake
1
−1000
1000



(asparagine)


R744
AA transporter
Hext <==> Gln[c]
Uptake
1
−1000
1000



(glutamine)


R1023
6-phosphogluconolactonase
GL6P[c] ==> 6PG[c]
Pentose Phosphate
0
0
1000





Pathway


R1022
glucose-6-phosphate
G6P[c] + NADP[c] <==> GL6P[c] +
Pentose Phosphate
1
−1000
1000



dehydrogenase (c-G6PDH)
NADPH[c]
Pathway


R1025
ribulose-phosphate 3-
Ru5P[c] <==>X5P[c]
Pentose Phosphate
1
−1000
1000



epimerase (cRuPepimerase)

Pathway


R1024
phosphogluconate
6PG[c] + NADP[c] ==> CO2[c] +
Pentose Phosphate
0
0
1000



dehydrogenase
NADPH[c] + Ru5P[c]
Pathway



(decarboxylating)



(c6-PGDH)


R999
CO2export
CO2[c] <==>
Excretion
1
−1000
1000


R1000
biomass export
biomass <==>
Excretion
1
−1000
1000


R745
O2-diffusion
<==> O2[c]
Uptake
1
−1000
1000


R770
G1P transporter
G1P[p] + P[c] <==> G1P[c] + P[p]
Internal Transport
1
−1000
1000


R774
glucose transporter
Glc[c] <==> Glc[p]
Internal Transport
1
−1000
1000


R775
triosephosphat/P
GAP[p] + P[c] <==> GAP[c] + P[p]
Internal Transport
1
−1000
1000



translocator (TPT1 GAP)


R776
triosephosphat/P
DHAP[p] + P[c] <==> DHAP[c] + P[p]
Internal Transport
1
−1000
1000



translocator (TPT2 DHAP)


R777
triosephosphat/P
3PG[p] + P[c] <==> 3PG[c] + P[p]
Internal Transport
1
−1000
1000



translocator (TPT3 3-PGA)


R778
phosphoenolpyruvate/
PEP[p] + P[c] <==> PEP[c] + P[p]
Internal Transport
1
−1000
1000



phosphat transporter


R780
malate/2OG transporter
2OG[c] + Mal[p] <==> 2OG[p] + Mal[c]
Internal Transport
1
−1000
1000


R781
malate/fumarate
Fum[p] + Mal[c] <==> Fum[c] + Mal[p]
Internal Transport
1
−1000
1000



transporter


R782
malate/glutamate
Glu[p] + Mal[c] <==> Glu[c] + Mal[p]
Internal Transport
1
−1000
1000



transporter


R783
malate/aspartate
Asp[p] + Mal[c] <==> Asp[c] + Mal[p]
Internal Transport
1
−1000
1000



transporter


R748
OAA/malate transporter
Mal[m] + OAA[c] <==> Mal[c] + OAA[m]
Internal Transport
1
−1000
1000


R749
OAA/2OG transporter
2OG[m] + OAA[c] <==> 2OG[c] + OAA[m]
Internal Transport
1
−1000
1000


R750
OAA/succinate transporter
OAA[c] + Succ[m] <==> OAA[m] + Succ[c]
Internal Transport
1
−1000
1000


R751
OAA/citrate transporter
Cit[m] + OAA[c] <==> Cit[c] + OAA[m]
Internal Transport
1
−1000
1000


R752
OAA/aspartate transporter
Asp[m] + OAA[c] <==> Asp[c] + OAA[m]
Internal Transport
1
−1000
1000


R756
succinate/malate
Mal[m] + Succ[c] <==> Mal[c] + Succ[m]
Internal Transport
1
−1000
1000



transporter


R755
succinate/P transporter
P[c] + Succ[m] <==> P[m] + Succ[c]
Internal Transport
1
−1000
1000


R757
malate/P transporter
Mal[m] + P[c] <==> Mal[c] + P[m]
Internal Transport
1
−1000
1000


R758
2OG/citrate transporter
2OG[m] + Cit[c] <==> 2OG[c] + Cit[m]
Internal Transport
1
−1000
1000


R759
2OG/succinate transporter
2OG[c] + Succ[m] <==> 2OG[m] + Succ[c]
Internal Transport
1
−1000
1000


R760
malate/citrate transporter
Cit[c] + Mal[m] <==> Cit[m] + Mal[c]
Internal Transport
1
−1000
1000


R761
succinate/citrate
Cit[c] + Succ[m] <==> Cit[m] + Succ[c]
Internal Transport
1
−1000
1000



transporter


R1021
mal transporter
Mal[p] <==> Mal[c]
Internal Transport
1
−1000
1000


R1011
pyruvate transporter (p)
Pyr[c] <==> Pyr[p]
Internal Transport
1
−1000
1000


R1008
malate/citrate transporter
Cit[p] + Mal[c] <==> Cit[c] + Mal[p]
Internal Transport
1
−1000
1000


R1010
malate/OAA transporter
Mal[c] + OAA[p] <==> Mal[p] + OAA[c]
Internal Transport
1
−1000
1000


R795
succinate/fumarate
Fum[m] + Succ[c] <==> Fum[c] + Succ[m]
Internal Transport
1
−1000
1000



transporter


R1027
invertase
sucrose[c] ==> Frc[c] + Glc[c]
Starch Sucrose
0
0
1000





Metabolism


R771
phosphate transporter
P[c] <==> P[p]
Internal Transport
1
−1000
1000


R996
ethanol export
Eth[c]<==>
Excretion
1
−1000
1000


R997
lactate export
Lac[c]<==>
Excretion
1
−1000
1000


R993
H2S diffusion (cm)
<==>H2S[c]
Uptake
1
−1000
1000


R762
phosphate transporter
P[m] <==> P[c]
Internal Transport
1
−1000
1000


R763
ATP/ADP transporter
ADP[m] + ATP[c] <==> ADP[c] + ATP[m]
Internal Transport
1
−1000
1000


R764
GABA/glutamate transporter
Gaba[m] + Glu[c] <==> Gaba[c] + Glu[m]
Internal Transport
1
−1000
1000


R766
CO2-diffusion
CO2[c] <==> CO2[m]
Internal Transport
1
−1000
1000


R767
O2-diffusion
O2[c] <==> O2[m]
Internal Transport
1
−1000
1000


R768
NH3-diffusion
NH3[c] <==> NH3[m]
Internal Transport
1
−1000
1000


R1016
AA transporter p (serine)
Ser[c] <==> Ser[m]
Internal Transport
1
−1000
1000


R1018
AA transporter m (gly)
Gly[c] <==> Gly[m]
Internal Transport
1
−1000
1000


R794
malate/2OG transporter
2OG[m] + Mal[c] <==> 2OG[c] + Mal[m]
Internal Transport
1
−1000
1000


R1026
X5P/P transporter
P[p] + X5P[c] <==> P[c] + X5P[p]
Internal Transport
1
−1000
1000


R772
ATP/AD P transporter
ADP[p] + ATP[c] <==> ADP[c] + ATP[p]
Internal Transport
1
−1000
1000


R994
H2S diffusion (p)
H2S[c] ==> H2S[p]
Internal Transport
0
0
1000


R790
folate transporter (THF)
THF[c] <==> THF[p]
Internal Transport
1
−1000
1000


R789
CO2-diffusion
CO2[c] <==> CO2[p]
Internal Transport
1
−1000
1000


R785
AA transporter (glutamine)
Gln[c] <==> Gln[p]
Internal Transport
1
−1000
1000


R786
AA transporter (citrulline)
Citru[c] <==> Citru[p]
Internal Transport
1
−1000
1000


R787
acetate diffusion
AcA[c] <==>AcA[p]
Internal Transport
1
−1000
1000


R1019
AA transporter p (gly)
Gly[p] <==> Gly[c]
Internal Transport
1
−1000
1000


R1017
AA transporter m (serine)
Ser[p] <==> Ser[c]
Internal Transport
1
−1000
1000


R940
succinate-CoA ligase
ATP[p] + CoA[p] + Succ[p] <==> ADP[p] +
TCA Cycle
1
−1000
1000



(ADP-forming)
P[p] + SuccCoA[p]


R791
folate transporter
MTHF[c] <==> MTHF[p]
Internal Transport
1
−1000
1000



(MTHF)


R793
folate transporter (FTHF)
FTHF[c] <==> FTHF[p]
Internal Transport
1
−1000
1000


R792
folate transporter
METTHF[c] <==> METTHF[p]
Internal Transport
1
−1000
1000



(METTHF)


R788
NH3S-diffusion
NH3[p] <==> NH3[c]
Internal Transport
1
−1000
1000


R1028
anthranilate synthase
Ch[p] + Gln[p] ==> Ant[p] + Glu[p] + Pyr[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R1029
anthranilate phosphori-
Ant[p] + PRPP[p] ==> PA[p] + PP[p]
Phenylalanine
0
0
1000



bosyltransferase

Tyrosine Tryptophan





Biosynthesis


R1030
phosphoribosylanthranilate
PA[p] <==> CDRP[p]
Phenylalanine
1
−1000
1000



isomerase

Tyrosine Tryptophan





Biosynthesis


R1031
indole-3-glycerol-
CDRP[p] ==> CO2[p] + I3GP[p]
Phenylalanine
0
0
1000



phosphate synthase

Tyrosine Tryptophan





Biosynthesis


R1032
tryptophan synthesis
I3GP[p] + Ser[p] ==> GAP[p] + Trp[p]
Phenylalanine
0
0
1000





Tyrosine Tryptophan





Biosynthesis


R840
UDP-glucuronate
UDPGlu[c] ==> CO2[c] + UDPXyl[c]
Starch Sucrose
0
0
1000



decarboxylase

Metabolism


R842
arabinoxylan synthesis
2 UDPAra[c] + 3 UDPXyl[c] ==> 5 AraXyl[c] +
Starch Sucrose
0
0
1000



(simpl.)
5 UDP[c]
Metabolism


R841
UDP-arabinose 4-epimerase
UDPAra[c] <==> UDPXyl[c]
Amino Sugar Nucleotide
1
−1000
1000





Sugar Metabolism


R843
cellulose synthase (UDP-
UDPGlc[c] ==> Cel[c] + UDP[c]
Starch Sucrose
0
0
1000



forming) (simpl.)

Metabolism


R838
glucan synthase complex
UDPGlc[c] ==> Bglucan[c] + UDP[c]
Starch Sucrose
0
0
1000





Metabolism


R839
UDP-glucose
2 NAD[c] + UDPGlc[c] ==> 2 NADH[c] +
Starch Sucrose
0
0
1000



6-dehydrogenase
UDPGlu[c]
Metabolism


R1033
UDP-glucose
UDPGlc[c] <==> UDPGal[c]
Amino Sugar Nucleotide
1
−1000
1000



4-epimerase

Sugar Metabolism


R1034
mannose-6-phosphate
F6P[c] <==> Man6P[c]
Fructose Mannose
1
−1000
1000



isomerase

Metabolism


R1035
phosphomannomutase
Man6P[c] <==> Man1P[c]
Fructose Mannose
1
−1000
1000





Metabolism


R1036
mannose-1-phosphate
GTP[c] + Man1P[c] <==> GDPMan[c] +
Fructose Mannose
1
−1000
1000



guanylyltransferase
PP[c]
Metabolism


R1037
nucleoside-diphosphate
ATP[c] + GDP[c] <==> ADP[c] + GTP[c]
Purine Metabolism
1
−1000
1000



kinase(cNDPkin: GDP)


R1040
pyruvate dehydrogenase
CoA[p] + NAD[p] + Pyr[p] ==> AcCoA[p] +
Glycolysis
0
0
1000



complex
CO2[p] + NADH[p]
Gluconeogenesis


R1041
C140synthesis
7 ATP[p] + 7 AcCoA[p] + 6 NADH[p] +
Lipids
0
0
1000




6 NADPH[p] ==> 7 ADP[p] + C140 + 7 CoA[p] +




6 NAD[p] + 6 NADP[p] + 7 P[p]


R1044
C180synthesis
ATP[p] + AcCoA[p] + C160 + NADH[p] +
Lipids
0
0
1000




NADPH[p] ==> ADP[p] + C180 + CoA[p] +




NAD[p] + NADP[p] + P[p]


R1042
C160synthesis
ATP[p] + AcCoA[p] + C140 + NADH[p] +
Lipids
0
0
1000




NADPH[p] ==> ADP[p] + C160 + CoA[p] +




NAD[p] + NADP[p] + P[p]


R1043
C161synthesis
C160 + NADPH[p] ==> C161 + NADP[p]
Lipids
0
0
1000


R1045
C181synthesis
C180 + NADPH[p] ==> C181 + NADP[p]
Lipids
0
0
1000


R1046
C182synthesis
C181 + NADPH[p] ==> C182 + NADP[p]
Lipids
0
0
1000


R1047
C183synthesis
C182 + NADPH[p] ==> C183 + NADP[p]
Lipids
0
0
1000


R1048
ATP citrate lyase
ATP[c] + Cit[c] + CoA[c] ==> ADP[c] +
Lipids
0
0
1000




AcCoA[c] + OAA[cl + P[c]


R1049
C200synthesis (cytosol)
ATP[c] + AcCoA[c] + C180 + NADH[c] +
Lipids
0
0
1000




NADPH[c] ==> ADP[c] + C200 + CoA[c] +




NAD[c] + NADP[c] + P[c]


R1003
adenosylhomocysteinase
SAH[c] <==> ADN[c] + HOMOCys[c]
Cysteine Methionine
1
−1000
1000





Metabolism


R1006
methionine synthase
HOMOCys[c] + MTHF[c] ==> Met[c] +
Cysteine Methionine
0
0
1000



(cMS)
THF[c]
Metabolism


R1002
methionine adenosyl-
ATP[c] + Met[c] ==> PP[c] + P[c] + SAM[c]
Cysteine Methionine
0
0
1000



transferase

Metabolism


R1005
homocysteine S-
HOMOCys[c] + SAM[c] ==> Met[c] + SAH[c]
Cysteine Methionine
0
0
1000



methyltransferase

Metabolism


R1051
glycerol-3-phosphate
DHAP[c] + NADH[c] <==> G3P[c] + NAD[c]
Lipids
1
−1000
1000



dehydrogenase


R1053
glycerol 3-phosphate O-
G3P[c] + acylCoA[c] ==> CoA[c] +
Lipids
0
0
1000



acetyltransferase
acylG3P[c]


R1054
1-acylglycerol 3-
acylCoA[c] + acylG3P[c] ==> CoA[c] +
Lipids
0
0
1000



phosphate acyltransferase
DAG3P[c]


R1055
phosphatidate phosphatase
DAG3P[c] ==> DAG[c] + P[c]
Lipids
0
0
1000


R1056
diglyceride acyltransferase
DAG[c] + acylCoA[c] ==> CoA[c] + TAG
Lipids
0
0
1000


R1052
Long-chain-fatty-acid
ATP[c] + CoA[c] + ffa ==> AMP[c] + PP[c] +
Lipids
0
0
1000



CoA ligase
acylCoA[c]


R1057
diacylglycerol-choline
CDPChol[c] + DAG[c] ==> CMP[c] + PC[c]
Lipids
0
0
1000



phosphotransferase


R1058
serine decarboxylase
Ser[c] ==> CO2[c] + EA[c]
Lipids
0
0
1000


R1059
ethanolamine kinase
ATP[c] + EA[c] ==> ADP[c] + phEA[c]
Lipids
0
0
1000


R1060
phosphoethanolamine N-
3 SAM[c] + phEA[c] ==> 3 SAH[c] + pChol[c]
Lipids
0
0
1000



methyltransferase


R1061
cholinephosphate
CTP[c] + pChol[c] ==> CDPChol[c] + PP[c]
Lipids
0
0
1000



cytidylyltransferase


R1062
cytidylate kinase
ATP[c] + CMP[c] <==> ADP[c] + CDP[c]
Lipids
1
−1000
1000


R1063
nucleoside-diphosphate
ATP[c] + CDP[c] <==> ADP[c] + CTP[c]
Lipids
1
−1000
1000



kinase


R1064
phosphatidate
CTP[c] + DAG3P[c] ==> CDPDAG[c] + PP[c]
Lipids
0
0
1000



cytidylyltransferase


R1065
CDP-diacylglycerol-
CDPDAG[c] + Ser[c] ==> CMP[c] + pSer[c]
Lipids
0
0
1000



serine O-



phosphatidyltransferase


R1066
phosphatidylserine
pSer[c] ==> CO2[c] + PEA
Lipids
0
0
1000



decarboxylase


R1069
phospholipid:diacylglycerol
DAG[c] + PC[c] ==> LPC + TAG
Lipids
0
0
1000



acyltransferase


R1067
ethanolamine-phosphate
CTP[c] + phEA[c] ==> CDPEA[c] + PP[c]
Lipids
0
0
1000



cytidylyltransferase


R1068
ethanolaminephospho-
CDPEA[c] + DAG[c] ==> CMP[c] + PEA
Lipids
0
0
1000



transferase


R1071
glycerol-3-phosphate
DHAP[p] + NADH[p] <==> G3P[p] + NAD[p]
Lipids
1
−1000
1000



dehydrogenase (p)


R1073
glycerol 3-phosphate O-
G3P[p] + acylCoA[p] ==> CoA[p] +
Lipids
0
0
1000



acyltransferase (p)
acylG3P[p]


R1074
1-acylglycerol 3-
acylCoA[p] + acylG3P[p] ==> CoA[p] +
Lipids
0
0
1000



phosphate acyltransferase
DAG3P[p]



(p)


R1075
phosphatidate phosphatase
DAG3P[p] ==> DAG[p] + P[p]
Lipids
0
0
1000


R1077
UDPGalactose:DAG
DAG[p] + UDPGal[c] ==> MGDG[p] + UDP[c]
Lipids
0
0
1000



galactosyltransferase


R1078
digalactosyldiacylglycerol
MGDG[p] + UDPGal[c] ==> DGDG[p] +
Lipids
0
0
1000



synthase
UDP[c]


R1072
Long-chain-fatty-acid
ATP[p] + CoA[p] + ffa ==> AMP[p] + PP[p] +
Lipids
0
0
1000



CoA ligase (p)
acylCoA[p]


R998
biomasssynthesis
3.71 ATP[m] + 0.0617 Ala[c] + 0.0174
Biomass
0
0
1000




AraX-yl[c] + 0.052 Arg[c] + 0.0662 Asp[c] +




0.0076 Bglucan[c] + 0.1343 Cel[c] + 0.0177




Cys[p] + 0.1121 Glu[c] + 0.0598 Gly[p] +




0.015 His[p] + 0.0295 Ile[p] + 0.0624 Leu[p] +




0.0265 Lys[p] + 0.015 Met[p] + 0.0295 Phe[p] +




0.0407 Pro[p] + 0.0478 Ser[p] + 0.023 TAG +




0.0313 Thr[p] + 0.0062 Trp[p] + 0.0219 Tyr[p] +




0.0469 Val[p] + 0.0075 ffa + 4.5956 starch[p] +




0.0477 sucrose[c] + 0.0353 pentosan + 0.0042




PL + 0.0018 GL ==> 3.71 ADP[m] + 3.71 P[m] +




biomass


R1038
PentosanProteinsynthesis
0.0573 Ala[c] + 0.0943 Arg[c] + 0.0918 Asp[c] +
Biomass
0
0
1000




0.0223 Cys[p] + 0.1718 Glu[c] + 0.0468 Gly[p] +




0.0243 His[p] + 0.0403 Ile[p] + 0.0853 Leu[p] +




0.0403 Lys[p] + 0.0233 Met[p] + 0.0508 Phe[p] +




0.0488 Pro[p] + 0.0523 Ser[p] + 0.0388 Thr[p] +




0.0133 Trp[p] + 0.0413 Tyr[p] + 0.0573




Val[p] ==> pentosanProtein


R1039
pentosanSynthesis
0.0455 GDPMan[c] + 0.0364 UDPAra[c] +
Biomass
0
0
1000




0.0455 UDPGal[c] + 0.6545 UDPGlc[c] +




0.0909 UDPGlu[c] + 0.0364 UDPXyl[c] +




0.091 pentosanProtein ==> 0.0455 GDP[c] +




0.8637 UDP[c] + pentosan


R1050
fattyacidsSynthesis
0.0032 C140 + 0.1826 C160 + 0.0036 C161 +
Lipids
0
0
1000




0.0212 C180 + 0.3986 C181 + 0.3679 C182 +




0.0146 C183 + 0.0082 C200 ==> ffa


R1070
phospholipidSynthesis
0.12 LPC + 0.44 PC[c] + 0.44 PEA ==> P[c] + PL
Lipids
0
0
1000


R1079
glycolipidSynthesis
0.5 DGDG[p] + 0.5 MGDG[p] ==> GL
Lipids
0
0
1000


R1080
LysineExport
Lys[p]<==>
Excretion
1
+1000
1000
















TABLE 4







abbreviations of metabolite names










Metabolite

Metabolite
Metabolite


name
Metabolite description
Compartment
KEGGID





13BPG[c]
1,3-Bisphospho-D-glycerate
Cytosol
C00236


13BPG[p]
1,3-Bisphospho-D-glycerate
Plastid
C00236


2AHB[p]
(S)-2-Aceto-2-hydroxybutanoate
Plastid
C06006


2IPM[p]
(2S)-2-Isopropylmalate
Plastid
C02504


2OB[p]
2-Oxobutanoate
Plastid
C00109


2OG[c]
2-Oxoglutarate
Cytosol
C00026


2OG[m]
2-Oxoglutarate
Mitochondrion
C00026


2OG[p]
2-Oxoglutarate
Plastid
C00026


2PG[c]
2-Phospho-D-glycerate
Cytosol
C00631


2PG[p]
2-Phospho-D-glycerate
Plastid
C00631


3DHQ[p]
3-Dehydroquinate
Plastid
C00944


3DSh[p]
3-Dehydroshikimate
Plastid
C02637


3IPM[p]
3-Isopropylmalate
Plastid
C04411


3PG[c]
3-Phospho-D-glycerate
Cytosol
C00197


3PG[p]
3-Phospho-D-glycerate
Plastid
C00197


6PG[c]
6-Phospho-D-gluconate
Cytosol
C00345


6PG[p]
6-Phospho-D-gluconate
Plastid
C00345


ADN[c]
Adenosine
Cytosol
C00212


ADP[c]
ADP
Cytosol
C00008


ADP[m]
ADP
Mitochondrion
C00008


ADP[p]
ADP
Plastid
C00008


ADPglc[c]
ADP-glucose
Cytosol
C00498


ADPglc[p]
ADP-glucose
Plastid
C00498


AICAR[p]
5-Phosphoribosyl-4-carbamoyl-5-aminoimidazole
Plastid
C04677


AMP[c]
AMP
Cytosol
C00020


AMP[p]
AMP
Plastid
C00020


ATP[c]
ATP
Cytosol
C00002


ATP[m]
ATP
Mitochondrion
C00002


ATP[p]
ATP
Plastid
C00002


AcA[c]
Acetate
Cytosol
C00033


AcA[p]
Acetate
Plastid
C00033


AcAl[c]
Acetaldehyde
Cytosol
C00084


AcCoA[c]
Acetyl-CoA
Cytosol
C00024


AcCoA[m]
Acetyl-CoA
Mitochondrion
C00024


AcCoA[p]
Acetyl-CoA
Plastid
C00024


AcGluP[p]
N-Acetyl-L-glutamate 5-phosphate
Plastid
C04133


AcGluSA[p]
N-Acetyl-L-glutamate 5-semialdehyde
Plastid
C01250


AcGlu[p]
N-Acetyl-L-glutamate
Plastid
C00624


AcLac[p]
2-Acetolactate
Plastid
C00900


AcOr[p]
N-Acetylornithine
Plastid
C00437


AcSer[p]
O-Acetyl-L-serine
Plastid
C00979


Agn[p]
L-Arogenate
Plastid
C00826


Ala[c]
L-Alanine
Cytosol
C00041


Ant[p]
Anthranilate
Plastid
C00108


AraXyl[c]
Arabinoxylan
Cytosol
C01889


ArgSucc[c]
L-Argininosuccinate
Cytosol
C03406


Arg[c]
L-Arginine
Cytosol
C00062


Asn[c]
L-Asparagine
Cytosol
C00152


AspSA[p]
L-Aspartate 4-semialdehyde
Plastid
C00441


Asp[c]
L-Aspartate
Cytosol
C00049


Asp[m]
L-Aspartate
Mitochondrion
C00049


Asp[p]
L-Aspartate
Plastid
C00049


Asuc[p]
Adenylosuccinate
Plastid
C03794


Bglucan[c]
beta-D-Glucan
Cytosol
C00551


C140
Myristic acid (C14:0)

C06424


C160
Palmitic acid (C16:0)

C00249


C161
Palmitoleic acid (C16:1)

C08362


C180
Stearic acid (C18:0)

C01530


C181
Oleic acid (C18:1)

C00712


C182
Linoleic acid (C18:2)

C01595


C183
alpha-Linolenic acid (C18:3)

C06427


C200
Arachidonic acid (C20:0)

C00219


CDPChol[c]
CDP-choline
Cytosol
C00307


CDPDAG[c]
CDP-diacylglycerol
Cytosol
C00269


CDPEA[c]
CDP-ethanolamine
Cytosol
C00570


CDP[c]
CDP
Cytosol
C00112


CDRP[p]
1-(2-Carboxyphenylamino)-1-deoxy-D-ribulose 5-
Plastid
C01302



phosphate


CMP[c]
CMP
Cytosol
C00055


CO2[c]
CO2
Cytosol
C00011


CO2[m]
CO2
Mitochondrion
C00011


CO2[p]
CO2
Plastid
C00011


CP[p]
Carbamoyl phosphate
Plastid
C00169


CTP[c]
CTP
Cytosol
C00063


Cel[c]
Cellulose
Cytosol
C00760


Ch[p]
Chorismate
Plastid
C00251


Cit[c]
Citrate
Cytosol
C00158


Cit[m]
Citrate
Mitochondrion
C00158


Cit[p]
Citrate
Plastid
C00158


Citru[c]
L-Citrulline
Cytosol
C00327


Citru[p]
L-Citrulline
Plastid
C00327


CoA[c]
CoA
Cytosol
C00010


CoA[m]
CoA
Mitochondrion
C00010


CoA[p]
CoA
Plastid
C00010


CysTh[p]
L-Cystathionine
Plastid
C02291


Cys[p]
L-Cysteine
Plastid
C00097


DAG3P[c]
1,2-Diacyl-sn-glycerol 3-phosphate
Cytosol
C00416


DAG3P[p]
1,2-Diacyl-sn-glycerol 3-phosphate
Plastid
C00416


DAG[c]
1,2-Diacyl-sn-glycerol
Cytosol
C00641


DAG[p]
1,2-Diacyl-sn-glycerol
Plastid
C00641


DAH7P[p]
2-Dehydro-3-deoxy-D-arabino-heptonate 7-phosphate
Plastid
C04691


DAH[p]
LL-2,6-Diaminoheptanedioate
Plastid
C00666


DGDG[p]
Digalactosyl-diacylglycerol
Plastid
C06037


DHAP[c]
Glycerone phosphate
Cytosol
C00111


DHAP[p]
Glycerone phosphate
Plastid
C00111


DIV[p]
2,3-Dihydroxy-isovalerate
Plastid
C04039


DMV[p]
2,3-Dihydroxy-3-methylvalerate
Plastid
C04104


DPA[p]
L-2,3-Dihydrodipicolinate
Plastid
C03340


E4P[p]
D-Erythrose 4-phosphate
Plastid
C00279


EA[c]
Ethanolamine
Cytosol
C00189


EPSP[p]
5-O-(1-Carboxyvinyl)-3-phosphoshikimate
Plastid
C01269


Eth[c]
Ethanol
Cytosol
C00469


F16P[c]
D-Fructose 1,6-bisphosphate
Cytosol
C00354


F16P[p]
D-Fructose 1,6-bisphosphate
Plastid
C00354


F6P[c]
D-Fructose 6-phosphate
Cytosol
C00085


F6P[p]
D-Fructose 6-phosphate
Plastid
C00085


FTHF[c]
10-Formyltetrahydrofolate
Cytosol
C00234


FTHF[p]
10-Formyltetrahydrofolate
Plastid
C00234


For[c]
Formate
Cytosol
C00058


Frc[c]
D-Fructose
Cytosol
C00095


Fum[c]
Fumarate
Cytosol
C00122


Fum[m]
Fumarate
Mitochondrion
C00122


Fum[p]
Fumarate
Plastid
C00122


G1P[c]
D-Glucose 1-phosphate
Cytosol
C00103


G1P[p]
D-Glucose 1-phosphate
Plastid
C00103


G3P[c]
Glycerol-3-phosphate
Cytosol
C00093


G3P[p]
Glycerol-3-phosphate
Plastid
C00093


G6P[c]
D-Glucose 6-phosphate
Cytosol
C00092


G6P[p]
D-Glucose 6-phosphate
Plastid
C00092


GAP[c]
D-Glyceraldehyde 3-phosphate
Cytosol
C00118


GAP[p]
D-Glyceraldehyde 3-phosphate
Plastid
C00118


GDPMan[c]
GDP-mannose
Cytosol
C00096


GDP[c]
GDP
Cytosol
C00035


GDP[p]
GDP
Plastid
C00035


GL6P[c]
6-Phospho-D-glucono-1,5-lactone
Cytosol
C01236


GL6P[p]
6-Phospho-D-glucono-1,5-lactone
Plastid
C01236


GTP[c]
GTP
Cytosol
C00044


GTP[p]
GTP
Plastid
C00044


Gaba[c]
4-Aminobutanoate
Cytosol
C00334


Gaba[m]
4-Aminobutanoate
Mitochondrion
C00334


Glc[c]
D-Glucose
Cytosol
C00031


Glc[p]
D-Glucose
Plastid
C00031


Gln[c]
L-Glutamine
Cytosol
C00064


Gln[p]
L-Glutamine
Plastid
C00064


GluSA[p]
L-Glutamate 5-semialdehyde
Plastid
C01165


Glu[c]
L-Glutamate
Cytosol
C00025


Glu[m]
L-Glutamate
Mitochondrion
C00025


Glu[p]
L-Glutamate
Plastid
C00025


Glx[c]
Glyoxylate
Cytosol
C00048


Gly[c]
Glycine
Cytosol
C00037


Gly[m]
Glycine
Mitochondrion
C00037


Gly[p]
Glycine
Plastid
C00037


H2S[c]
Hydrogen sulfide
Cytosol
C00283


H2S[p]
Hydrogen sulfide
Plastid
C00283


HOMOCys[c]
L-Homocysteine
Cytosol
C00155


HOMOCys[p]
L-Homocysteine
Plastid
C00155


HOMOSer[p]
L-Homoserine
Plastid
C00263


Hext
Hydron (extraplasmatic)

C00080


His[p]
L-Histidine
Plastid
C00135


HolP[p]
L-Histidinol phosphate
Plastid
C01100


Hol[p]
L-Histidinol
Plastid
C00860


I3GP[p]
Indole-3-glycerol phosphate
Plastid
C03506


IAP[p]
Imidazole-acetol phosphate
Plastid
C01267


IGP[p]
D-erythro-Imidazole-glycerol phosphate
Plastid
C04666


IMP[p]
Inosine monophosphate
Plastid
C00130


IPO[p]
(2S)-2-Isopropyl-3-oxosuccinate
Plastid
C04236


Icit[c]
Isocitrate
Cytosol
C00311


Icit[m]
Isocitrate
Mitochondrion
C00311


Ile[p]
L-Isoleucine
Plastid
C00407


LPC
2-Lysophosphatidylcholine

C04230


Lac[c]
L-Lactate
Cytosol
C00186


Leu[p]
L-Leucine
Plastid
C00123


Lys[p]
L-Lysine
Plastid
C00047


METHF[c]
5-Methyltetrahydrofolate
Cytosol
C00440


METTHF[c]
5,10-Methylenetetrahydrofolate
Cytosol
C00143


METTHF[m]
5,10-Methylenetetrahydrofolate
Mitochondrion
C00143


METTHF[p]
5,10-Methylenetetrahydrofolate
Plastid
C00143


MGDG[p]
Monogalactosyl-diacylglycerol
Plastid
C03692


MTHF[c]
5-Methyltetrahydrofolate
Cytosol
C00440


MTHF[p]
5-Methyltetrahydrofolate
Plastid
C00440


Mal[c]
L-Malate
Cytosol
C00149


Mal[m]
L-Malate
Mitochondrion
C00149


Mal[p]
L-Malate
Plastid
C00149


Malt[p]
Maltose
Plastid
C00208


Man1P[c]
D-Mannose 1-phosphate
Cytosol
C00636


Man6P[c]
D-Mannose 6-phosphate
Cytosol
C00275


Met[c]
L-Methionine
Cytosol
C00073


Met[p]
L-Methionine
Plastid
C00074


NAD[c]
NAD+
Cytosol
C00003


NAD[m]
NAD+
Mitochondrion
C00003


NAD[p]
NAD+
Plastid
C00003


NADH[c]
NADH
Cytosol
C00004


NADH[m]
NADH
Mitochondrion
C00004


NADH[p]
NADH
Plastid
C00004


NADP[c]
NADP+
Cytosol
C00006


NADP[m]
NADP+
Mitochondrion
C00006


NADP[p]
NADP+
Plastid
C00006


NADPH[c]
NADPH
Cytosol
C00005


NADPH[m]
NADPH
Mitochondrion
C00005


NADPH[p]
NADPH
Plastid
C00005


NH3[c]
NH3
Cytosol
C00014


NH3[m]
NH3
Mitochondrion
C00014


NH3[p]
NH3
Plastid
C00014


O2[c]
Oxygen
Cytosol
C00007


O2[m]
Oxygen
Mitochondrion
C00007


OAA[c]
Oxaloacetate
Cytosol
C00036


OAA[m]
Oxaloacetate
Mitochondrion
C00036


OAA[p]
Oxaloacetate
Plastid
C00036


OIC[p]
2-Oxoisocaproate
Plastid
C00233


OIV[p]
2-Oxoisovalerate
Plastid
C00141


OMV[p]
2-Oxo-3-methylvalerate
Plastid
C03465


Or[p]
L-Ornithine
Plastid
C00077


Oxl[c]
Oxalate
Cytosol
C00209


PHOMOSer[p]
O-Phospho-L-homoserine
Plastid
C01102


PA[p]
N-(5-Phospho-D-ribosyl)anthranilate
Plastid
C04302


PAsp[p]
L-4-Aspartyl phosphate
Plastid
C03082


PC[c]
Phosphatidylcholine
Cytosol
C00157


PEA
Phosphatidylethanolamine

C00350


PEP[c]
Phosphoenolpyruvate
Cytosol
C00074


PEP[p]
Phosphoenolpyruvate
Plastid
C00074


PHPyr[p]
3-Phosphohydroxypyruvate
Plastid
C03232


PP[c]
Diphosphate
Cytosol
C00013


PP[p]
Diphosphate
Plastid
C00013


PR_AICARP[p]
Phosphoribosyl-formimino-AICAR-phosphate
Plastid
C04896


PR_AMP[p]
Phosphoribosyl-AMP
Plastid
C02741


PR_ATP[p]
Phosphoribosyl-ATP
Plastid
C02739


PRE[p]
Prephenate
Plastid
C00254


PRFICA[p]
1-(5′-Phosphoribosyl)-5-formamido-4-
Plastid
C04734



imidazolecarboxamide


PRPP[p]
5-Phospho-alpha-D-ribose 1-diphosphate
Plastid
C00119


PRu_AICARP[p]
Phosphoribulosyl-formimino-AICAR-phosphate
Plastid
C04916


P[c]
Phosphate
Cytosol
C00009


P[m]
Phosphate
Mitochondrion
C00009


P[p]
Phosphate
Plastid
C00009


Phe[p]
L-Phenylalanine
Plastid
C00079


Pro[p]
L-Proline
Plastid
C00148


Pser[p]
3-Phosphoserine
Plastid
C01005


Pyr[c]
Pyruvate
Cytosol
C00022


Pyr[m]
Pyruvate
Mitochondrion
C00022


Pyr[p]
Pyruvate
Plastid
C00022


PyrrC[p]
L-1-Pyrroline-5-carboxylate
Plastid
C03912


QH2[m]
Ubiquinol
Mitochondrion
C00390


Q[m]
Ubiquinone
Mitochondrion
C00399


R5P[p]
D-Ribose 5-phosphate
Plastid
C00117


Ru15P[p]
D-Ribulose 1,5-bisphosphate
Plastid
C01182


Ru5P[c]
D-Ribulose 5-phosphate
Cytosol
C00199


Ru5P[p]
D-Ribulose 5-phosphate
Plastid
C00199


S6P[c]
Sucrose 6′-phosphate
Cytosol
C02591


S7P[p]
Sedoheptulose 7-phosphate
Plastid
C05382


SAH[c]
S-Adenosyl-L-homocysteine
Cytosol
C00021


SAM[c]
S-Adenosyl-L-methionine
Cytosol
C00019


Ser[c]
L-Serine
Cytosol
C00065


Ser[m]
L-Serine
Mitochondrion
C00065


Ser[p]
L-Serine
Plastid
C00065


Sh3P[p]
Shikimate 3-phosphate
Plastid
C03175


Sh[p]
Shikimate
Plastid
C00493


SuccAH[p]
N-Succinyl-2-L-amino-6-oxoheptanedioate
Plastid
C04462


SuccCoA[m]
Succinyl-CoA
Mitochondrion
C00091


SuccCoA[p]
Succinyl-CoA
Plastid
C00091


SuccDAH[p]
N-Succinyl-LL-2,6-diaminoheptanedioate
Plastid
C04421


SuccSAl[m]
Succinate semialdehyde
Mitochondrion
C00232


Succ[c]
Succinate
Cytosol
C00042


Succ[m]
Succinate
Mitochondrion
C00042


Succ[p]
Succinate
Plastid
C00042


TAG
Triacylglycerol

C00422


THDPA[p]
2,3,4,5-Tetrahydrodipicolinate
Plastid
C03972


THF[c]
Tetrahydrofolate
Cytosol
C00101


THF[m]
Tetrahydrofolate
Mitochondrion
C00101


THF[p]
Tetrahydrofolate
Plastid
C00101


Thr[p]
L-Threonine
Plastid
C00188


Trp[p]
L-Tryptophan
Plastid
C00078


Tyr[p]
L-Tyrosine
Plastid
C00082


UDPAra[c]
UDP-L-arabinose
Cytosol
C00935


UDPGal[c]
UDP-D-galactose
Cytosol
C00052


UDPGlc[c]
UDP-glucose
Cytosol
C00029


UDPGlu[c]
UDP-glucuronate
Cytosol
C00167


UDPXyl[c]
UDP-D-xylose
Cytosol
C00190


UDP[c]
UDP
Cytosol
C00015


UTP[c]
UTP
Cytosol
C00075


Val[p]
L-Valine
Plastid
C00183


X5P[c]
D-Xylose-5-phosphate
Cytosol
C06814


X5P[p]
D-Xylose-5-phosphate
Plastid
C06814


acylCoA[c]
Acyl-CoA
Cytosol
C00040


acylCoA[p]
Acyl-CoA
Plastid
C00040


acylG3P[c]
1-Acyl-sn-glycerol 3-phosphate
Cytosol
C00681


acylG3P[p]
1-Acyl-sn-glycerol 3-phosphate
Plastid
C00681


biomass
biomass


ffa
free fatty acids


mDAH[p]
meso-2,6-Diaminoheptanedioate
Plastid
C00680


pChol[c]
Phosphorylcholine
Cytosol
C00588


pSer[c]
Phosphatidylserine
Cytosol
C02737


phEA[c]
Phosphoethanolamine
Cytosol
C00346


starch[p]
Starch
Plastid
C00369


sucrose[c]
Sucrose
Cytosol
C00089


pentosan
pentosan


pentosanProtein
pentosan protein


PL
phospholipids


GL
glycolipids








Claims
  • 1. A method for identifying at least one metabolic conversion step, the modulation of which increases the amount of a metabolite of interest in a plant cell, plant or plant part, said method comprising: (a) establishing a stoichiometric network model for the metabolism of the plant cell, plant or plant part including the synthesis pathway for the metabolite of interest;(b) identifying at least one candidate metabolic conversion step by applying at least one algorithm of Growth-coupled Design; and(c) validating the at least one candidate metabolic conversion step by a constraint-based modeling approach in the stoichiometric network model, wherein an increase in the metabolite of interest occurring in said constraint-based modeling approach is indicative for a metabolic conversion step, the modulation of which increases the amount of the metabolite of interest in the plant cell, plant or plant part.
  • 2. The method of claim 1, wherein said modulation of a metabolic conversion step encompasses decreasing or increasing the activity of at least one enzyme catalyzing the metabolic conversion step in the plant cell.
  • 3. The method of claim 1, wherein said stoichiometric network model for the metabolism of the plant cell, plant or plant part comprises all relevant metabolic conversion steps of the anabolic and catabolic pathways of the metabolism of the plant cell, plant or plant part and wherein each metabolic conversion step is defined by its underlying reaction stoichiometry.
  • 4. The method of claim 1, wherein said at least one algorithm for solving the Growth-coupled Design (i) is capable of at least calculating the amount of the metabolite of interest obtained in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced and (ii) is capable of thereby identifying at least one metabolic enzymatic conversion step the reduction of which yields the maximum amount for the metabolite of interest.
  • 5. The method of claim 4, wherein the amount of the metabolite of interest is calculated based on the calculated amount of biomass.
  • 6. The method of claim 5, wherein said amount of biomass is calculated based on (i) fixed substrate uptake rates for the metabolic network of the plant cell, plant or plant part and/or (ii) the plant-specific nutritional composition in the stoichiometric network model under conditions where at least one metabolic enzymatic conversion step is reduced or enhanced.
  • 7. The method of claim 4, wherein said at least one algorithm for solving the Growth-coupled Design is selected from the group consisting of: OptKnock, RobustKnock and OptGene.
  • 8. The method of claim 7, wherein OptKnock and/or RobustKnock are to be used if one to four metabolic enzymatic conversion step(s), the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified.
  • 9. The method of claim 7, wherein OptGene is to be used if more than four metabolic enzymatic conversion steps, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, shall be identified.
  • 10. The method of claim 1, wherein said plant cell, plant or plant part is a rice cell, rice plant, rice plant part, or rice seed.
  • 11. The method of claim 1, wherein said metabolite of interest is an amino acid, a fatty acid, or a carbohydrate.
  • 12. The method of claim 1, wherein steps (a) to (c) of said method are automated by implementation on a data processing device.
  • 13. The method of claim 1, wherein said method further comprises the further step of: (d) determining whether the metabolic enzymatic conversion step validated in step (c) increases the metabolite of interest in the plant cell, plant or plant part by modulating the said metabolic enzymatic conversion step in a plant cell, plant or plant part in vivo.
  • 14. A method for generating a plant cell, plant or plant part which produces an increased amount of a metabolite of interest when compared to a control, said method comprising: (a) identifying a metabolic conversion step, the modulation of which increases a metabolite of interest in a plant cell, plant or plant part, by the method of claim 1; and(b) stably modulating the said metabolic conversion step such that the amount of the metabolite of interest is increased in vivo in a plant cell, plant or plant part.
  • 15. A method for the manufacture of a metabolite of interest comprising the steps of the method of claim 14 and the further step of obtaining the metabolite of interest from the generated plant cell, plant or plant part.
  • 16. A plant cell, plant or plant part obtainable by the method according to claim 14, which produces an increased amount of a metabolite of interest when compared to a control.
  • 17. A device comprising a data processor having tangibly embedded least one of the algorithms of the invention.
  • 18. The device of claim 17, wherein the device is a data processing device.
  • 19. A data carrier comprising the data defining the stoichiometric network model established according to claim 1.
Priority Claims (1)
Number Date Country Kind
12195896.1 Dec 2012 EP regional
PCT Information
Filing Document Filing Date Country Kind
PCT/IB2013/060656 12/5/2013 WO 00
Provisional Applications (1)
Number Date Country
61733924 Dec 2012 US